TOPICAL COMPOSITIONS FOR REGULATING THE OILY/SHINY APPEARANCE OF SKIN

Abstract: The present invention relates to methods for inhibiting sebaceous gland activity in mammalian skin comprising administration of a topical composition comprising dehydroacetic acid or pharmaceuti cally acceptable salts thereof, and a dermatologically-acceptable carrier. The present invention also relates to methods and topical compositions further comprising agents which regulate the oily and/or shiny appearance of skin, and agents which treat acne and related skin disorders in mammalian skin and scalp. Methods of reducing sebum synthesis with the use of dehydroacetic acid, methods of regulating the oily and/or shiny appearance of skin, and methods of treating acne and other skin disorders are also encompassed by the present invention.

Description: TOPICAL COMPOSITIONS FOR REGULATING THE OILY/SHINY APPEARANCE OF SKIN Technical Field The present invention relates to methods for inhibiting sebaceous gland activity in mammalian skin using dehydroacetic acid, or pharmaceutically acceptable salts thereof, in a dermatologically-acceptable carrier The present invention also relates to methods and topical compositions further comprising agents which regulate the oily and/or shiny appearance of skin, and agents which treat acne and related skin disorders in mammalian skm and scalp Background of the Invention Sebum or skin oil is produced in the sebaceous glands located m the pilosebaceous apparatus of the skin and reaches the skm surface through ducts of the hair follicles The presence of excessive amounts of sebum on the skin surface often results m an unattractive cosmetic condition commonly known as "oily skm " Dependmg on the regions of sebaceous gland activity and the level of sebum secretion, the population is often classified by skin type, e g , dry, normal, oily, combined dry/normal, combmed dry/oily, or combined normal/oily skin (the latter two classes hereinafter alternatively referred to as "combination skm") Persons having an oily skin type or a combination skm type typically manifest an oily and/or shmy skm appearance between cleansings Following initial cleansmg of the skm, this oily or shiny appearance generally increases as the day progresses In order to avoid such appearance, individuals must throughout the day either cleanse the skin, blot the skm, apply oil absorbing powders to the skin, or take some other measure to minimize the appearance of oil or shme Therefore, it has been desired in the art to provide topical compositions which reduce sebum synthesis by the sebaceous glands and minimize the appearance of oil and/or shme on the skm, especially oily or combination skm Furthermore, in the field of cosmetic or make-up compositions, several topical compositions which are said to be designed for controlling oily and/or shmy skm are known in the art For example, facial moisturizers and make-up said to have such property are known However, an oily or a combination skm type presents a particular challenge to the formulation of make-up mtended for facial use, mcludmg foundations As oil accumulates on the facial skm of such individuals, oil breakthrough occurs In other words, the make-up fails to sufficiently mask the oil such that an oily or shmy skin appearance results As a result, the coverage and wear resistance of the make-up tends to be reduced It would be desirable to provide a make-up composition that mamtams a high degree of coverage and wear resistance after application to all skm types, mcludmg oily and combmation skin, preferably substantially as originally applied While certain formulations have been designed in an attempt to control the oily and/or shiny appearance of skin, there remains a need to provide improved topical compositions for reducing sebum synthesis by the sebaceous glands and minimizing the appearance of skin oil and/or shine. In addition to minimizing oil and/or shine, such compositions should not unacceptably discolor the skin. Therefore, there is a particular need to provide improved skin care compositions and make-up which (i) reduces sebum synthesis by the sebaceous glands, (ii) minimizes the appearance of skin oil and/or shine, (iii) provides and maintains an even (i.e., uniform coverage) complexion and acceptable skin tone for extended periods after application, and or (iv) which has extended wear resistance after application. Dehydroacetic acid and its pharmaceutically acceptable salts have heretofore been used as preservatives, antimicrobial agents, and bactericides in cosmetic formulations, food packaging and veterinary drugs. These utilities and many others are further described in the Final Report on the Safety Assessment of Sodium Dehydroacetate and Dehydroacetic Acid, Journal of the American College of Toxicology, Vol. 4, No. 3, pp. 123-159 (1985). It has surprisingly been found that dehydroacetic acid and its pharmaceutically acceptable salts are useful when topically applied for inhibiting sebaceous gland activity. Since the sebaceous gland is a principal source of oil on mammalian skin and scalp, a primary benefit of controlling sebaceous gland activity (e.g., sebum secretion) includes a reduction in the level of oil found in skin and hair. As a result, dehydroacetic acid is useful for regulating the appearance of oily and/or shiny skin, including oily and combination skin. It has also surprisingly been found that topical compositions containing these compounds in the form of a facial make-up composition minimize the appearance of skin oil and/or shine, provide and maintain substantially uniform coverage and an acceptable skin tone for extended periods after application, and/or have extended wear resistance after application. Because of the ability of dehydroacetic acid to control sebaceous gland activity, it has also been found to be useful in treating acne and related skin disorders in mammalian skin and scalp, such as, eczema, seborrhea, impetigo, psoriasis, rosacea. It is an object of the present invention to provide topical compositions for inhibiting sebaceous gland activity which results in effectively regulating the oily and/or shiny appearance of mammalian skin, especially facial skin. It is a further object of this invention to provide such topical compositions which regulate the appearance of oily and/or shiny mammalian skin, provide and maintain substantially uniform coverage for extended periods after application to the skin, provide and maintain an acceptable skin tone for extended periods after application to the skin, and/or have extended wear resistance after application to the skin. Another object of the present invention is to provide methods of regulating the appearance of oily and/or shiny mammalian skin and methods of reducing sebum synthesis by the pilosebaceous glands. It is a further object of the present invention to provide topical compositions for treatment of acne and related skin disorders m mammalian skin and scalp Other objects of the subject invention will be apparent from the disclosure which follows Summary of the Invention The present invention relates to a method of inhibiting sebaceous gland activity in mammalian skm and scalp, such method comprises the step of administering a certain kmd of topical composition to the skm or scalp of a mammal susceptible to having excessive sebaceous gland activity These topical compositions comprise a safe and effective amount of dehydroacetic acid or pharmaceutically-acceptable salts, derivatives, or tautomers thereof, and a dermatologically- acceptable carrier The present invention also relates to methods of regulating the oily and/or shmy skm appearance usmg these compositions In another embodiment, the present invention also relates to topical compositions for inhibiting sebaceous gland activity These compositions comprise a safe and effective amount of dehydroacetic acid or pharmaceutically-acceptable salts, derivatives, or tautomers thereof, a sebum absorbing material, and a dermatologically-acceptable earner Alternative embodiments relate to topical composition which further comprise sebum spreadmg reduction mateπals Methods of inhibiting excessive sebaceous gland activity using these above compositions are also within the purview of this invention In another embodiment, the present invention relates to a topical composition for regulating oily and/or shmy skin appearance These compositions comprise a safe and effective amount of dehydroacetic acid or pharmaceutically-acceptable salts, derivatives, or tautomers thereof, an oily and/or shiny skm appearance control active, and a dermatologically-acceptable carrier Methods of regulating oily and/or shiny skin appearance with the above compositions are also within the purview of this invention In still another embodiment, the present mvention relates to methods and topical compositions for treating acne in mammalian skin or scalp These compositions comprise a safe and effective amount of dehydroacetic acid or pharmaceutically-acceptable salts, denvatives, or tautomers thereof, an ancillary anti-acne active, and a dermatologically-acceptable carrier Also included in this embodiment is a method of treating acne with a composition compπsmg a safe and effective amount of dehydroacetic acid or pharmaceutically-acceptable salts, denvatives, or tautomers thereof, and a dermatologically-acceptable earner All percentages and ratios used herein, unless otherwise mdicated, are by weight and all measurements made are at 25°C, unless otherwise designated The mvention hereof can comprise, consist of, or consist essentially of, the essential as well as optional mgredients and components described therem Detailed Description of the Invention The compositions of the present invention are useful as topical compositions, 1 e , they are suitable for topical administration to mammals As used herein, "topical" means applied to the surface of the skm or scalp The compositions of the subject invention are administered topically to a biological subject 1 e , by the direct laying on or spreading of the composition on the skm or scalp of the subject The topical compositions comprise a safe and effective amount of dehydroacetic acid (or a pharmaceutically acceptable salt thereof) and a dermatologically-acceptable topical carrier As used herein "comprising" means that other steps and ingredients which do not affect the end result can be added This term encompasses the terms "consisting of and "consisting essentially of The phrase "consisting essentially of means that the composition may include additional mgredients, but only if the additional mgredients do not materially alter the basic and novel characteristics of the claimed compositions or methods As used herein, "safe and effective amount" means a sufficient amount of a compound, composition or other material described by this phrase to significantly induce a positive modification m the condition being treated, but low enough to avoid significant side effects (e g , significant skin irritation or sensitization), withm the scope of sound judgment of the skilled artisan The safe and effective amount of the compound, composition or other material may vary with the particular skm being treated, the age and physical condition of the biological subject bemg treated, the seventy of the condition, the duration of the treatment, the nature of concurrent therapy, the specific compound, composition or other material employed, the particular cosmetically acceptable topical carrier utilized, and like factors within the knowledge and expertise of the skilled artisan The term "dermatologically-acceptable," as used herem, means that the compositions or components thereof so described are suitable for use m contact with mammalian skin without undue toxicity, incompatibility, instability, allergic response, and the like As used herein, "inhibiting sebaceous gland activity" means preventing, retardmg, reducmg and/or minimizing the production of sebum As used herem, "regulating the oily and/or shiny appearance of skm" means preventmg, retardmg and/or arresting the appearance of oil and/or shme on the skm By regulating the oily and/or shmy appearance of the skin, one or more of the following benefits are achieved there is a noticeable decrease m the visible oil, shme, greasmess, or highlights on the skm, the skm is substantially free from visible oihness, shme, or highlights, the skm has a substantially matte finish, the user has a more uniform complexion Regulating the oily and/or shmy appearance of the skm may result in more uniform and lasting coverage of the skm by the composition, mcreased wear resistance of the composition and or a decrease in the incidence or seventy of skm oil breakmg through the composition so as to become visibly apparent In addition, the resultmg reduction of greasmess of the skm (e g , tactile sensation) also prevents and/or reduces other detrimental effects associated with excessive skin oihness, such as, itchmess, redness, irritation, and inflammation As used herein, "mixtures" is meant to mclude a simple combination of matenals and any compounds that may result from their combmation I. Dehydroacetic Acid The compositions of this invention comprise dehydroacetic acid, having the structure or pharmaceutically acceptable salts, derivatives, or tautomers thereof (hereafter referred to as "dehydroacetic acid or pharmaceutically acceptable salts thereof), in an amount that is safe and effective for (1) reducing sebum synthesis by the pilosebaceous glands, (u) regulatmg the oily and/or sh y appearance of the skm, and (in) treating acne and other related skm disorders m mammalian skm and scalp The compositions of the present mvention comprise from about 0 1% to about 25% by weight of the composition, preferably from about 0 1% to about 10%, more preferably from about 0 5% to about 5%, and most preferably from about 1% to about 5% of dehydroacetic acid or dermatologically acceptable salts, derivatives, or tautomers thereof As used herein, "pharmaceutically acceptable" means that the salts of dehydroacetic are suitable for use in contact with the tissues of mammals to which they will be exposed without undue toxicity, incompatibility, instability, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio As used herem, "related skin disorders m mammalian skm and scalp" means medical conditions resulting from oilness of the skm, such as, eczema, seborrhea, impetigo, psoriasis, rosacea The technical name for dehydroacetic acid is 3-Acetyl-6-methyl-2H-pyran- 2,4(3H)-dιone and can be commercially purchased under the tradename Unisept DHA ® from Universal Preserv-A-Chem, Inc , located in Brooklyn, NY Dermatologically acceptable salts mclude alkali metal salts, such as sodium and potassium, alkaline earth metal salts, such as calcium and magnesium, non-toxic heavy metal salts, ammonium salts, and tπalkylammonium salts, such as tπmethyammonium and tπethylammonium Sodium, potassium, and ammonium salts of dehydroacetic acid are preferred Denvatives of dehydroacetic acid mclude, but are not limited to, any compounds wherein the CH3 groups are individually or m combmation replaced by amides, esters, ammo groups, alkyls, and alcohol esters Tautomers of dehydroacetic acid are the isomers of dehydroacetic acid which can change into one another with great ease so that they ordinarily exist m equilibrium Thus, tautomers of dehydroacetic acid can be described as havmg the chemical formula C Hgθ4 and generally havmg the structure above Dehydroacetic acid is water soluble and has no significant formulation issues Although the activity of dehydroacetic acid m inhibiting sebaceous gland activity is not compromised by pH, risk of eye irritation, however, is expected to mcrease significantly as formulation pH decreases II. Ancillary Actives The compositions of the present invention can further comprise one or more ancillary actives capable of functioning in different ways to enhance the benefits of dehydroacetic acid and/or to provide other benefits. These ancillary actives (1) enhance the reduction of sebum synthesis, (n) help regulate the oily and/or shiny appearance of skm, or (in) provide anti-acne benefits which complement the benefits of dehydroacetic acid The ancillary active mgredients useful herein are categorized by their cosmetic and/or therapeutic benefit or their postulated mode of action However, it is to be understood that the ancillary active mgredients useful herem can m some mstances provide more than one cosmetic and/or therapeutic benefit or operate via more than one mode of action Therefore, classifications herem are made for the sake of convenience and are not intended to limit the active ingredient to that particular application or applications listed A. Oil Control Agents Sebum absorbing materials The compositions of the present mvention can also contam oil sebum absorbing materials also known as sequestering agents Nonhmiting examples are clays (e g., bentomte), talcs, silicas, starches, polymeric absorbents (e g , MICROSPONGES 5647 and POLYTRAP, both commercially available from Advanced Polymer Systems, Inc of Redwood City, California, USA), and other such materials. MICROSPONGES 5647 is a polymer mixture denved from styrene, methyl methacrylate, and hydrogel acrylate/methacrylate Other useful sebum absorbmg materials are disclosed m U.S. Pat No. 4,940,578, to Yoshihara, T. et al., issued July 10, 1990, U.S. Pat No 4,885,109 to Umemoto, I et al , issued Dec. 5, 1989; U S. Pat. No. 4,536,399, to Flynn, R G. et al., issued Aug 20, 1985; U.S Pat No. 4,489,058, to Lay, G.E. et al., issued Dec. 18, 1984; U S. Pat. No 4,619,826, to Lay, G.E. et al , issued Oct 28, 1986, U S. Pat. No. 4,388,301, to Klem, R W , issued June 14, 1983; and U.S. Pat No. 4,000,317, to Menda, W.C. et al , issued Dec. 28, 1976; U.S. Pat. No. 4,294,823, to Elliott, TJ. et al., issued Oct. 13, 1981, U.S Pat. No. 5,145,685, to Carmody, W.J., issued Sept. 8, 1992; U.S. Pat. No 5,386,003, to Greene, C.J. et al., issued Jan. 31, 1995; PCT Application WO 92/00724, published Jan. 23, 1992; all incorporated herem by reference. Sebum migration reduction material The compositions of the present mvention can also contain materials which reduce sebum spreadabihty. By reduction of sebum spreading/migration is meant that these materials retard or anest the migration or movement of sebum from the areas immediately near the sebaceous gland to the rest of the skm or hair Nonhmiting examples are cocamidopropyl hydroxysultaine in combmation with a quaternary hahde of N,N,N- tnalkylaminoalkylene gluconamide, as described m U.S. Pat No. 4,534,964, to Herstem, M.S. et al., issued Aug. 13, 1985; and further in combmation with ammonium lauryl sulfate and tnethanolamine lauryl sulfate, as described m U.S. Pat No. 4,529,588, to Smith, W P. et al., issued July 16, 1985; and straight cham dimethyl sihcone polymer havmg the formula (CH 3 ) 3 Sι -[OSι(CH3) 2 τn CH3 wherem n is a positive integer sufficient to provide a silicone polymer having a molecular weight of about 50,000 or more and a viscosity of about 10,000 centistokes or more, as described m U S Pat No 4,515,784, to Bogardus, R E et al , issued May 7, 1985, all of which are incorporated herem by reference in their enhrety B. Ancillary Sebosupressive Actives The compositions of the present invention can comprise one or more suitable ancillary sebosupressive actives (e g , in addition to dehydroacetic acid) in an amount that is safe and effective for regulatmg the oily and/or shiny appearance ( hereinafter referred to as "OSA") of the skin Without bemg limited by theory, it is believed that ancillary sebosuppressive actives decrease the sebum output of the pilosebaceous ducts of the skin, thereby reducmg surface oiliness Suitable OSA actives are those which effectively regulate the oily and/or shmy appearance of skin without unacceptably discoloring the skin, e g , unacceptably causing reddenmg or flushing of the skm Suitable ancillary sebosuppressive actives are descnbed in Karg, G et al , "Sebosupression," Cosmetics and Toiletries, vol 102, pp 140-146 (April 1987), U S pat No 4,593,021, to Hsia, S L et al , issued June 3, 1986, U S Pat No 4,587,235, to Bittler, D et al , issued May 6, 1986, U S pat No 4,529,587, to Green, M R , issued July 16, 1985, U S Pat No 4,210,654 to Bauer et al , issued July 1, 1980, U S Pat No 4,016,287, to Eberhardt et al , issued Apr 5, 1977, and U S Pat No 5,587,176, to Wanen, R et al , issued Dec 24, 1996, all of which are incorporated herein by reference in then: entirety Compounds that possess significant vasodilatory properties are typically unsuitable for use as ancillary actives Such vasodilatory compounds tend to cause unacceptable flushing or reddenmg of the skm such that then use, especially in facial applications, is not desirable For example, known vasodilators such as mcotinic acid are not suitable for use herein Although not preferred, such vasodilatory compounds may be added m amounts which would not trigger their vasodilatory properties Vasodilatory compounds may be added to the compositions of the present mvention preferably from about 0 0001% to about 1%, more preferably from about 0 001% to about 0 1% The exact amount will depend on the particular vasodilatory compound utilized since such agents very widely in potency Preferred compositions of this mvention comprise as ancillary sebosuppressive actives one or more compounds selected from the group consisting of vitamin B3 compound, tocopherol mcotmate, pyndoxme, panthenol, pantothenic acid, tioxolone (6-Hydro-2-oxo-l,3-benzoxathιole), hesperetm, and mixtures thereof As used herem, "vitamin B3 compound" means a compound havmg the formula Or whrem R is -CONH2 (e g , macmamide), -COOH (e g , nicotinic acid) or -CH20H (e g , notinyl alcohol), and derivatives hereof, and salts of any of the foregoing Exemplary denvatives of the foregomg vitamin B3 compounds mclude mcotmic acid esters, including non-vasodilahng esters of nicotinic acid, mcotinyl ammo acids, mcotinyl alcohol esters of carboxyhc acids, mcotmic acid N- oxide and macmamide N-oxide In a preferred embodiment, the ancillary sebosuppressive actives are substantially pure By substantially pure it is meant that the compound described by that phase is at least 90% pure, at least more preferably 95% pure, most preferably 99% pure In a prefened embodiment, the ancillary sebosuppressive active comprises macmamide, which is more preferably substantially pure macmamide Thus, the ancillary active may consist essentially of (a) macmamide, or (b) a mixture of (1) macmamide and (11) a compound selected from the group consisting of panthenol, pantothemc acid, pyπdoxme, tioxolone, and hesperetin Preferably, the composition compnses from about 0 01% to about 25%, by weight, of sebosuppressive active, more preferably from about 0 1% to about 10%, even more preferably from about 1% to about 5%, most preferably from about 2% to about 5% In an especially preferred embodiment, the topical composition comprises from about 2% to about 5%, by weight, of macmamide, which is preferably substantially pure macmamide When macmamide (a vitamm B 3 compound) is being used m the present mvention the following cautionary notes must be observed It has been found that certain compounds may negatively impact the skin benefits otherwise provided by the vitamm B3 compound Such compounds mclude ascorbic acid and N-acetyl cysteme Without intendmg to be bound or limited by theory, it is believed that these compounds may form large or poorly soluble complexes, e g , salts, with the vitamin B3 compound which reduce the availability of the vitamm B3 compound to the skm Such complexes are believed to have a relatively high molecular weight or are poorly soluble which decreases then availability to the skm Therefore, m one embodiment of the mvention, the compositions do not contam these compounds or compounds which are capable of forming similar complexes with the vitamm B3 compound In another embodiment, where the composition contams these compounds or compounds which are capable of forming complexes with the vitamm B3 compound, one or more of the approaches described herem for minimizing or preventing the formation of undesirable complexes are preferred For example, the impact of such compounds on the efficacy of the vitamm B3 compound decreases with a decrease m pH such that pH adjustments can be employed to minimize or obviate such effects For example, when the composition contams N-acetyl-L-cysteine, the pH of the composition is preferably adjusted to from about 2 to about 5, more preferably from about 3 to about 4 The adjustment of pH to obviate substantial impacts on efficacy is well within the level of ordinary skill m the art C. Ancillary Anti-Acne Actives Sebum also plays an important role in the pathogenesis of acne The ductal mcrease m sebum production results m an mcrease in certain bacteria, notably Propiontbacterium acnes, which can initiate a primary folhcular inflammation (e g , acne) Because of the role that sebum plays in the etiology of acne, preventive measures are primarily concerned with reduction m the quantity of sebum present on the skin and underlying tissue Since dehydroacetic acid has been surprisingly found to reduce sebum synthesis, the compositions of the present mvention can suitably be used to treat acne and can contain an ancillary anti-acne active selected from the group consisting of antimicrobial agents, antiandrogens, comedolytic/keratolytic agents, and anti-mflammatory agents As used herein "treating acne" means preventmg, retarding and/or arresting the process of acne formation, and/or clearing or healing existing lesions As used herein, "anti-acne active" means an active capable of preventmg, retardmg and/or arresting the process of acne formation, and/or clearmg or healmg existmg lesions Comedolytic/keratolytic agents In a preferred composition useful m the subject mvention, a comedolytic agent and/or a keratolytic agents are mcluded as an active along with the dehydroacetic acid As used herem, the term "comedolytic agent" refers to any compound capable of rupturing a comedo As used herem, the term "keratolytic agent" refers to any compound capable of breakmg apart keratinocytes resultmg in exfoliation of the epidermis A safe and effective amount of a comedolytic agent and/or a keratolytic agent may be added to the composition useful m the subject mvention, preferably from about 0 05% to about 10% , more preferably from about 0 1% to about 5% Preferred comedolytic and keratolytic agents useful m the subject mvention are selected from the group consistmg of retmoids, salicylic acid, lactic acid, glycohc acid, cetyl betame, sulfur, and resorcinol Especially preferred is a combmation cetyl betame and salicylic acid In a preferred acne-treating composition useful m the subject mvention, a retinoid, preferably retmoic acid, is included as an active along with the dehydroacetic acid The mclusion of a retmoid mcreases the acne-treating benefits of the composition A safe and effective amount of a retmoid may be added to the compositions useful m the subject invention, preferably from about 0 001%> to about 5% by weight of the composition, more preferably from about 0 01% to about 5%, most preferably from about 0 01% to about 3% As used herem, "retmoid" mcludes all natural and/or synthetic analogs of Vitamm A or retinol-like compounds which possess die biological activity of Vitamm A m the skm as well as the geometric isomers and stereoisomers of these compounds, such as all-trans retmoic acid and 13-cιs-retmoιc acid Retmoids are also useful m providmg unexpected benefits m regulatmg skm condition, especially in therapeutically regulating signs of skm agmg, more especially wrinkles, lmes, and pores The retinoid for this particular benefit is preferably retmol, retmol esters (e g , C - C22 alkyl esters of retmol, including retmyl palmitate, retmyl acetate, retmyl propionate), retmal, and/or retmoic acid (mcludmg all-trans retmoic acid and/or 13-cιs-retιnoιc acid), more preferably retmoids other than retmoic acid These compounds are well known m the art and are commercially available from a number of sources, e g , Sigma Chemical Company (St Louis, MO), and Boerhmger Mannheim (Indianapolis, IN) Other retmoids which are useful herem are described m U S Patent Nos 4,677,120, issued Jun 30, 1987 to Parish et al , 4,885,311, issued Dec 5, 1989 to Parish et al , 5,049,584, issued Sep 17, 1991 to Purcell et al , 5,124,356, issued Jun 23, 1992 to Purcell et al , and Reissue 34,075, issued Sep 22, 1992 to Purcell et al Other suitable retmoids are tocopheryl- retinoate [tocopherol ester of retmoic acid (trans- or cis-), adapalene {6-[3-(l-adamantyl)-4- methoxyphenyl]-2-naphthoιc acid}, and tazarotene (ethyl 6-[2-(4,4-dιmethylthιochroman-6-yl)- ethynyljmcotmate) One or more retmoids may be used herem Prefened retmoids are retmol, retmyl palmitate, retmyl acetate, retmyl propionate, retinal and combmations thereof More preferred are retmol and retmyl propionate The retmoid may be mcluded as the substantially pure material, or as an extract obtained by suitable physical and or chemical isolation from natural (e g , plant) sources The retmoid is preferably substantially pure, more preferably essentially pure In a preferred embodiment, the compositions of the present invention contam a retinoid m combination with a vitamin B3 compound and dehydroacetic acid The vitamm B3 compound and retinoid provide unexpected benefits in reducing sebum synthesis and regulatmg skm condition, especially in therapeutically regulatmg signs of skm aging, more especially wrinkles, lmes, and pores (hereinafter referred to as "regulatmg skm condition") Without intending to be bound or otherwise limited by theory, it is believed that the vitamm B3 compound mcreases the conversion of certain retmoids to trans-retinoic acid, which is believed to be the biologically active form of the retinoid, to provide synergistic regulation of skm condition (namely, mcreased conversion for retmol, retmol esters, and retmal) In addition, the vitamin B3 compound unexpectedly mitigates redness, mflammation, dermatitis and the like which may otherwise be associated with topical application of retmoid (often referred to, and heremafter alternatively referred to as "retmoid dermatitis") Furthermore, the combmed vitamm B3 compound and retinoid tend to mcrease the amount and activity of thioredoxm, which tends to mcrease collagen expression levels via the protem AP-1 Therefore, the present mvention enables reduced active levels, and therefore reduced potential for retmoid dermatitis, while retammg significant positive skm conditioning benefits In addition, higher levels of retmoid may still be used to obtain greater skin conditioning efficacy, without undesn able retinoid dermatitis occurring The compositions of this invention may contam a safe and effective amount of the retmoid, such that the resultant composition is safe and effective for reducmg sebum synthesis, preventmg acne, and regulatmg skin condition The compositions preferably contam from about 0 001% to about 5% by weight of the composition, more preferably from about 0.01% to about 5%, most preferably from about 0.01%> to about 3%, retinoid. Retinol is most preferably used in an amount from about 0.01% to about 0.15%; retinol esters are most preferably used in an amount from about 0.01% to about 2% (e.g., about 1%); retinoic acids are most preferably used in an amount from about 0.01% to about 0.25%; tocopheryl-retinoate [tocopherol ester of retinoic acid (trans- or cis), adapalene {6-[3-(l-adamantyl)-4-methoxyphenyl]-2-naphthoic acid}, and tazarotene are most preferably used in an amount from about 0.01% to about 2%. When the composition contains a retinoid, the vitamin B3 compound is preferably used in an amount of from about 0.1% to about 10%, more preferably from about 2% to about 5%. Antimicrobial agents: In a preferred acne-treating composition useful in the subject invention, an antimicrobial agent is included as an active along with the dehydroacetic acid. The inclusion of an antimicrobial agent increases the acne-treating benefits of the composition. As used herein, "antimicrobial agent" means a compound capable of destroying microbes, preventing the development of microbes or preventing the pathogenic action of microbes. A safe and effective amount of an antimicrobial agent may be added to compositions of the subject invention, preferably from about 0.001% to about 10%, more preferably from about 0.01% to about 5%, also from about 0.05%> to about 2% or from about 0.05% to about 1% of the compositions. Preferred antimicrobial agents useful in the subject invention are benzoyl peroxide, erythromycin, tetracycline, clindamycin, and azelaic acid. Anti- inflammatory agents: An anti-inflammatory agent can be included as an active along with dehydroacetic acid, for treatment of acne. A safe and effective amount of an anti-inflammatory agent may be added to the compositions of the subject invention, preferably from about 0.1% to about 10%), more preferably from about 0.5%) to about 5%, by weight of the composition. The anti- inflammatory agent enhances the skin appearance benefits of the present invention, e.g., such agents contribute to a more uniform and acceptable skin tone. The exact amount of anti-inflammatory agent to be used in the compositions will depend on the particular anti-inflammatory agent utilized since such agents vary widely in potency. Steroidal anti-inflammatory agents, including but not limited to, corticosteroids such as hydrocortisone, hydroxyltriamcinolone, alpha-methyl dexamethasone, dexamethasone-phosphate, beclomethasone dipropionates, clobetasol valerate, desonide, desoxymethasone, desoxycorticosterone acetate, dexamethasone, dichlorisone, diflorasone diacetate, diflucortolone valerate, fluadrenolone, fluclorolone acetonide, fludrocortisone, flumethasone pivalate, fluosinolone acetonide, fluocinonide, flucortine butylesters, fluocortolone, fluprednidene (fluprednylidene) acetate, flurandrenolone, halcinonide, hydrocortisone acetate, hydrocortisone butyrate, methylprednisolone, triamcinolone acetonide, cortisone, cortodoxone, flucetonide, fludrocortisone, difluorosone diacetate, fluradrenolone, fludrocortisone, diflurosone diacetate, fluradrenolone acetonide, medrysone, amcinafel, amcinafide, betamethasone and the balance of its esters, chloropredmsone, chlorprednisone acetate, clocortelone, clescmolone, dichloπsone, diflurprednate, flucloromde, flumsolide, fluoromethalone, fluperolone, fluprednisolone, hydrocortisone valerate, hydrocortisone cyclopentylpropionate, hydrocortamate, mepredmsone, paramethasone, predmsolone, prednisone, beclomethasone dipropionate, tnamcinolone, and mixtures thereof may be used The preferred steroidal anti-inflammatory for use is hydrocortisone A second class of anti-mflammatory agents which is useful m the compositions mcludes the nonsteroidal anti-inflammatory agents The variety of compounds encompassed by this group are well-known to those skilled m the art For detailed disclosure of the chemical structure, synthesis, side effects, etc of non-steroidal anti-inflammatory agents, reference may be had to standard texts, mcludmg Anti-inflammatory and Anti-Rheumatic Drugs. K D Ramsford, Vol I-III, CRC Press, Boca Raton, (1985), and Anti-inflammatory Agents, Chemistry and Pharmacology. 1, R A Scherrer, et al , Academic Press, New York (1974), each incorporated herein by reference Specific non-steroidal anti-mflammatory agents useful m the composition invention mclude, but are not limited to 1) the oxicams, such as piroxicam, isoxicam, tenoxicam, sudoxicam, and CP-14,304, 2) the sahcylates, such as aspirin, disalcid, benorylate, tπlisate, safapryn, solpnn, diflumsal, and fendosal, 3) the acetic acid derivatives, such as diclofenac, fenclofenac, lndomethacin, suhndac, tolmetm, isoxepac, furofenac, tiopmac, zidometacm, acematacm, fentiazac, zomepirac, clmdanac, oxepmac, felbmac, and ketorolac, 4) the fenamates, such as mefenamic, meclofenamic, flufenamic, mflumic, and tolfenamic acids, 5) the propionic acid derivatives, such as lbuprofen, naproxen, benoxaprofen, flurbiprofen, ketoprofen, fenoprofen, fenbufen, indopropfen, pirprofen, carprofen, oxaprozin, pranoprofen, mrroprofen, tioxaprofen, suprofen, alrmnoprofen, and tiaprofemc, and 6) the pyrazoles, such as phenylbutazone, oxyphenbutazone, feprazone, azapropazone, and tπmethazone, 7) anti-oxidants, such as ascorbic acid (vitamm C) and its salts, ascorbyl esters of fatty acids, ascorbic acid derivatives (e g , magnesium ascorbyl phosphate), tocopherol (vitamm E), tocopherol sorbate, other esters of tocopherol (e g , acetate, succmate, linoleate) Mixtures of these non-steroidal anti-mflammatory agents may also be employed, as well as the dermatologically acceptable salts and esters of these agents For example, etofenamate, a flufenamic acid derivative, is particularly useful for topical application Of the nonsteroidal anti- mflammatory agents, lbuprofen, aspirin, naproxen, flufenamic acid, mefenamic acid, meclofenamic acid, piroxicam and felbmac are preferred, lbuprofen, naproxen, flufenamic acid, ascorbic acid, and tocopherol sorbate are most prefened Finally, so-called "natural" anti-mflammatory agents are useful m methods of the subject invention For example, candehlla wax, alpha bisabolol, aloe vera, Manjistha (extracted from plants in the genus Rubia, particularly Rubia Cordifoha), Guggal (extracted from plants m the genus Commiphora, particularly Commiphora Mukul), and green tea extract, may be used Antiandrogens In a preferred acne-treating composition useful m me subject mvention, an antiandrogen is included as an active along with dehydroacetic acid As used herem, "anti-androgen" means a compound capable of correcting androgen-related disorders by mterfermg with the action of androgens at their target organs The target organ for the subject mvention is mammalian skm A safe and effective amount of an antiandrogen may be added to the compositions useful m the subject invention, preferably from about 0 001% to about 5%, more preferably from about 0 001% to about 1% Antiandrogens which are androgen receptor antagonists, as well as, antiandrogens which are 5- reductase inhibitors are useful m the compositions of the subject invention Examples of such antiandrogens are more fully disclosed in U S Pat No 4,888,336, Holt, Metcalf and Levy, issued Dec 19, 1989, U S Pat No 5,110,939, Holt Metcalf and Levy, issued May 5, 1992, U S Pat No 5,120,742, Rasmusson and Reynolds, issued June 9, 1992, and U S Pat No 4,859,681, Rasmusson and Reynolds, issued Aug 22, 1989, all incorporated herem by reference See also Stewart, M and P Pochi. Antiandrogens and the Skm, International Society of Tropical Dermatology, Vol 17, No 3, pp 167—179 (1978), incorporated herem by reference in its entirety Preferred antiandrogens useful for compositions of the subject mvention are cyproterone acetate, finastende, chlormadmon acetate, 17-α propylmesterolone, 17-α estradiol acetate, dienoestrol diacetate, estradiol benzoate, inocoterone acetate, spirono-lactone, 11-α hydroxyprogestrone, and mixtures thereof III. Dermatologically Acceptable Carrier The compositions of the present invention compnse a dermatologically acceptable earner within which dehydroacetic acid is incorporated to enable dehydroacetic acid, ancillary actives, and optional other actives to be delivered to the skm at an appropriate concentration The earner can thus act as a diluent, dispersant, solvent, or the like for the actιve(s) which ensures that it can be applied to and distributed evenly over the selected target at an appropriate concentration The carrier may contain one or more dermatologically acceptable solid, semi-solid or liquid fillers, diluents, solvents, extenders and the like The carrier may be solid, semi-solid or liquid The earner can itself be inert or it can possess dermatological benefits of its own Concentrations of the carrier can vary with the carrier selected and the mtended concentrations of the essential and optional components Suitable earners mclude conventional or otherwise known earners that are dermatologically acceptable The carrier should also be physically and chemically compatible with the essential components described herem, and should not unduly impair stability, efficacy or other use benefits associated with the compositions of the present invention Prefened components of the compositions of this invention should be capable of being commingled in a manner such that there is no interaction which would substantially reduce the efficacy of the composition under ordinary use situations The type of earner utilized m the present invention depends on the type of product form desired for the composition The topical compositions useful in the subject invention may be made mto a wide variety of product forms such as are known m the art These mclude, but are not limited to, lotions, creams, gels, sticks, sprays, ointments, pastes, mousses and cosmetics (e g , solid, semi- solid, or liquid make-up, including foundations, eye-makeup, pigmented or non-pigmented lip treatments, e g , lipsticks, and the like) These product forms may comprise several types of earners mcludmg, but not limited to, solutions, aerosols, emulsions, gels, solids, and hposomes Preferred carriers contam a dermatologically acceptable, hydrophilic diluent As used herem, "diluent" mcludes materials m which dehydroacetic acid can be dispersed, dissolved, or otherwise incorporated Hydrophilic diluents mclude water, organic hydrophilic diluents such as lower monovalent alcohols (e g , Ci - C4) and low molecular weight glycols and polyols, mcludmg propylene glycol, polyethylene glycol (e g , Molecular Weight 200-600 g/mole), polypropylene glycol (e g , Molecular Weight 425-2025 g/mole), glycerol, butylene glycol, 1,2,4-butanetnol, sorbitol esters, 1,2,6-hexanetπol, ethanol, isopropanol, sorbitol esters, butanediol, ether propanol, ethoxylated ethers, propoxylated ethers and combmations thereof Water is a preferred diluent The composition preferably comprises from about 75% to about 99 99% of the hydrophilic diluent and dehydroacetic acid m the above described amounts Examples of suitable carriers which high hydrophobic diluents are described in U S Patent No 5,380,528, to Alban, N C et al , issued Jan 10, 1995, U S Patent No 5,420,118, to Alban, N C et al , issued May 30, 1995, both incorporated by reference herein m their entirety Aerosols accordmg to the subject mvention can be formed by addmg a propellant to a solution such as described above Exemplary propellants mclude chloro-fluonnated lower molecular weight hydrocarbons Additional propellants that are useful herem are described m Sagarin, Cosmetics Science and Technology, 2nd Edition, Vol 2, pp 443-465 (1972), incorporated herem by reference Aerosols are typically applied to the skm as a spray-on product Preferred carriers comprise an emulsion such as oil-m-water emulsions, water-m-oil emulsions, and water-in-sihcone emulsions As will be understood by the skilled artisan, a given component will distribute primarily mto either the water or oil/silicone phase, dependmg on the water solubility/dispersibihty of the component m the composition Dehydroacetic acid distnbutes pnmanly mto the aqueous phase Oil-in-water emulsions are especially prefened Emulsions according to the present invention generally contain a solution as described above and a hpid or oil Lipids and oils may be derived from animals, plants, or petroleum and may be natural or synthetic (1 e , man-made) Preferred emulsions also contain a humectant, such as glycerin Emulsions will preferably further contain from about 1%> to about 10%o, more preferably from about 2% to about 5%, of an emulsifier, based on the weight of the carrier Emulsifiers may be nonionic, anionic or cationic Suitable emulsifiers are disclosed m, for example, U S Patent 3,755,560, issued August 28, 1973, Dickert et al , U S Patent 4,421,769, issued December 20, 1983, Dixon et al , and McCutcheon's Detergents and Emulsifiers, North American Edition, pages 317-324 (1986), each incorporated herem by reference The emulsion may also contain an anti-foaming agent to minimize foammg upon application to the skin Anti-foammg agents include high molecular weight silicones and other matenals well known in the art for such use Suitable emulsions may have a wide range of viscosities, depending on the desned product form Exemplary low viscosity emulsions, which are prefened, have a viscosity of about 50 centistokes or less, more preferably about 10 centistokes or less, most preferably about 5 centistokes or less Preferred water-m-sihcone and oil-m-water emulsions are described in greater detail below a) Water-in-silicone emulsion Water-in-sihcone emulsions contain a contmuous silicone phase and a dispersed aqueous phase (l) Continuous silicone phase Preferred water- rn-silicone emulsions of the present invention comprise from about 1% to about 60%o, preferably from about 5% to about 40%, more preferably from about 10%> to about 20%, by weight of a contmuous silicone phase The contmuous silicone phase exists as an external phase that contains or sunounds the discontmuous aqueous phase described heremafter The contmuous silicone phase contams a polyorganosiloxane oil A preferred water-rn- sihcone emulsion system is formulated to provide an oxidatively stable vehicle for the optional retmoid The contmuous silicone phase of these prefened emulsions comprises between about 50%> and about 99 9% by weight of organopolysiloxane oil and less than about 50% by weight of a non- sihcone oil In an especially prefened embodiment, the contmuous silicone phase compnses at least about 50%), preferably from about 60% to about 99 9%, more preferably from about 70% to about 99 9%, and even more preferably from about 80%) to about 99 9%, polyorganosiloxane oil by weight of the contmuous silicone phase, and up to about 50% non-sihcone oils, preferably less about 40%, more preferably less than about 30%>, even more preferably less than about 10%>, and most preferably less than about 2%, by weight of the contmuous silicone phase These prefened emulsion systems provide more oxidative stability to the retmoid over extended penods of tune than comparable water- m-oil emulsions contaming lower concentrations of the polyorganosiloxane oil Concentrations of non-silicone oils in the contmuous silicone phase are minimized or avoided altogether so as to further enhance oxidative stability of the selected retmoid in the compositions Water-m-sihcone emulsions of this type are described in copendmg U S Patent Application Serial No 08/570,275, filed December 11, 1995, in the names of Joseph Michael Zukowski, Brent William Mason, Larry Richard Robinson and Greg George Hillebrand, incorporated herem by reference The organopolysiloxane oil for use m the composition may be volatile, non-volatile, or a mixture of volatile and non- volatile silicones The term "nonvolatile" as used in this context refers to those silicones that are liquid under ambient conditions and have a flash pomt (under one atmospheric of pressure) of or greater than about 100°C The term "volatile" as used in this context refers to all other silicone oils Suitable organopolysiloxanes can be selected from a wide variety of silicones spanning a broad range of volatilities and viscosities Examples of suitable organopolysiloxane oils mclude polyalkylsiloxanes, cyclic polyalkylsiloxanes, and polyalkylarylsiloxanes Polyalkylsiloxanes useful in the composition herem include polyalkylsiloxanes with viscosities of from about 0 5 to about 1,000,000 centistokes at 25°C Such polyalkylsiloxanes can be represented by the general chemical formula R3SιO[R2SιO] x SιR3 wherem R is an alkyl group havmg from one to about 30 carbon atoms (preferably R is methyl or ethyl, more preferably methyl, also mixed alkyl groups can be used in the same molecule), and x is an integer from 0 to about 10,000, chosen to achieve the desired molecular weight which can range to over about 10,000,000 Commercially available polyalkylsiloxanes mclude the polydimethylsiloxanes, which are also known as dimethicones, examples of which include the Vicasil® series sold by General Electnc Company and the Dow Corning® 200 series sold by Dow Corning Corporation Specific examples of suitable polydimethylsiloxanes mclude Dow Corning® 200 fluid havmg a viscosity of 0 65 centistokes and a boiling point of 100°C, Dow Corning® 225 fluid havmg a viscosity of 10 centistokes and a boiling pomt greater than 200°C, and Dow Corning® 200 fluids havmg viscosities of 50, 350, and 12,500 centistokes, respectively, and boiling pomts greater than 200°C Suitable dimethicones mclude those represented by the chemical formula (CH3)3SιO[(CH3)2SιO] x [CH 3 RSιO] y Sι(CH3)3 wherem R is straight or branched cham alkyl havmg from two to about 30 carbon atoms and x and y are each integers of 1 or greater selected to achieve the desired molecular weight which can range to over about 10,000,000 Examples of these alkyl-substituted dimethicones mclude cetyl dimethicone and lauryl dimethicone Cyclic polyalkylsiloxanes suitable for use m the composition mclude those represented by the chemical formula [SιR2-0] n wherem R is an alkyl group (preferably R is methyl or ethyl, more preferably methyl) and n is an mteger from about 3 to about 8, more preferably n is an mteger from about 3 to about 7, and most preferably n is an mteger from about 4 to about 6 When R is methyl, these matenals are typically refened to as cyclomethicones Commercially available cyclomethicones mclude Dow Corning® 244 fluid havmg a viscosity of 2 5 centistokes, and a boiling point of 172°C, which primarily contains the cyclomethicone tetramer (i.e. n=4), Dow Corning® 344 fluid having a viscosity of 2.5 centistokes and a boiling point of 178°C, which primarily contains the cyclomethicone pentamer (i.e. n=5), Dow Corning® 245 fluid having a viscosity of 4.2 centistokes and a boiling point of 205°C, which primarily contains a mixture of the cyclomethicone tetramer and pentamer (i.e. n=4 and 5), and Dow Corning® 345 fluid having a viscosity of 4.5 centistokes and a boiling point of 217°, which primarily contains a mixture of the cyclomethicone tetramer, pentamer, and hexamer (i.e. n=4, 5, and 6). Also useful are materials such as trimethylsiloxysilicate, which is a polymeric material conesponding to the general chemical formula [(CH2)3SiOj/2] χ [Siθ2]y, wherein x is an integer from about 1 to about 500 and y is an integer from about 1 to about 500. A commercially available trimethylsiloxysilicate is sold as a mixture with dimethicone as Dow Corning® 593 fluid. Dimethiconols are also suitable for use in the composition. These compounds can be represented by the chemical formulas R3SiO[R 2 SiO] χ SiR 2 OH and HOR 2 SiO[R2SiO] x SiR 2 OH wherein R is an alkyl group (preferably R is methyl or ethyl, more preferably methyl) and x is an integer from 0 to about 500, chosen to achieve the desired molecular weight. Commercially available dimethiconols are typically sold as mixtures with dimethicone or cyclomethicone (e.g. Dow Corning® 1401, 1402, and 1403 fluids). Polyalkylaryl siloxanes are also suitable for use in the composition. Polymethylphenyl siloxanes having viscosities from about 15 to about 65 centistokes at 25°C are especially useful. Prefened for use herein are organopolysiloxanes selected from the group consisting of polyalkylsiloxanes, alkyl substituted dimethicones, cyclomethicones, trimethylsiloxysilicates, dimethiconols, polyalkylaryl siloxanes, and mixtures thereof. More preferred for use herein are polyalkylsiloxanes and cyclomethicones. Prefened among the polyalkylsiloxanes are dimethicones. As stated above, the continuous silicone phase may contain one or more non-silicone oils. Concentrations of non-silicone oils in the continuous silicone phase are preferably minimized or avoided altogether so as to further enhance oxidative stability of the selected retinoid in the compositions. Suitable non-silicone oils have a melting point of about 25°C or less under about one atmosphere of pressure. Examples of non-silicone oils suitable for use in the continuous silicone phase are those well known in the chemical arts in topical personal care products in the form of water-in-oil emulsions, e.g., mineral oil, vegetable oils, synthetic oils, semisynthetic oils, etc.. (ii) Dispersed aqueous phase The topical compositions of the present invention comprise from about 30% to about 90%, more preferably from about 50%> to about 85%>, and most preferably from about 70% to about 80% of a dispersed aqueous phase. In emulsion technology, the term "dispersed phase" is a term well- known to one skilled in the art which means that the phase exists as small particles or droplets that are suspended in and sunounded by a continuous phase. The dispersed phase is also known as the internal or discontinuous phase. The dispersed aqueous phase is a dispersion of small aqueous particles or droplets suspended m and sunounded by the contmuous silicone phase described hereinbefore The aqueous phase can be water, or a combmation of water and one or more water soluble or dispersible ingredients Nonlimiting examples of such optional mgredients include thickeners, acids, bases, salts, chelants, gums, water-soluble or dispersible alcohols and polyols, buffers, preservatives, sunscreening agents, colormgs, and the like The topical compositions of the present mvention will typically comprise from about 25% to about 90%>, preferably from about 40%> to about 80%, more preferably from about 60% to about 80%, water m the dispersed aqueous phase by weight of the composition (in) Emulsifier for dispersmg the aqueous phase The water-in-silicone emulsions of die present invention preferably comprise an emulsifier In a prefened embodiment, the composition contams from about 0 1% to about 10% emulsifier, more preferably from about 0 5% to about 7 5%, most preferably from about 1%> to about 5%, emulsifier by weight of the composition The emulsifier helps disperse and suspend the aqueous phase withm the contmuous silicone phase A wide variety of emulsifying agents can be employed herem to form the prefened water-in- silicone emulsion Known or conventional emulsifying agents can be used m the composition, provided that the selected emulsifying agent is chemically and physically compatible with essential components of the composition, and provides the desired dispersion charactenstics Suitable emulsifiers mclude silicone emulsifiers, non-sihcon-containing emulsifiers, and mixtures thereof, known by those skilled in the art for use m topical personal care products Preferably these emulsifiers have an HLB value of or less than about 14, more preferably from about 2 to about 14, and most preferably from about 4 to about 14 Emulsifiers havmg an HLB value outside of these ranges can be used in combmation with other emulsifiers to achieve an effective weighted average HLB for the combmation that falls within these ranges Silicone emulsifiers are prefened A wide vanety of silicone emulsifiers are useful herem These silicone emulsifiers are typically organically modified organopolysiloxanes, also known to those skilled m the art as silicone surfactants Useful silicone emulsifiers mclude dimethicone copolyols These mateπals are polydrmethyl siloxanes which have been modified to mclude polyether side chams such as polyethylene oxide chams, polypropylene oxide chams, mixtures of these chams, and polyether chams contammg moieties derived from both ethylene oxide and propylene oxide Other examples mclude alkyl-modified dimethicone copolyols, l e , compounds which contam C2-C30 pendant side chams Still other useful dimethicone copolyols mclude materials having various cationic, anionic, amphoteric, and zwitteriomc pendant moieties The dimethicone copolyol emulsifiers useful herem can be descnbed by the following general structure CH 3 CH 3 CH 3 CH 3 CH 3 I I I I I CH,— Si— O- -Si— -o -Si— -O -Si— -o -Si— CH 3 I I CH 3 CH 3 R _2 CH 3 wherem R is C1-C30 straight, branched, or cyclic alkyl and R^ is selected from the group consistmg of -(CH 2 ) n -0-(CH 2 CHR3θ) m -H, and ~(CH 2 ) n -0-(CH 2 CHR 3 0) m -(CH 2 CHR 4 0) 0 -H, wherem n is an mteger from 3 to about 10, R 3 and R 4 are selected from the group consisting of H and C1-C6 straight or branched cham alkyl such that R- and R 4 are not simultaneously the same, and m, o, x, and y are selected such that the molecule has an overall molecular weight from about 200 to about 10,000,000, with m, o, x, and y being independently selected from mtegers of zero or greater such that m and o are not bom simultaneously zero, and z bemg mdependently selected from mtegers of 1 or greater It is recognized that positional isomers of these copolyols can be achieved The chemical representations depicted above for the R^ moieties contammg the R 3 and R 4 groups are not meant to be limiting but are shown as such for convenience Also useful herein, although not strictly classified as dimethicone copolyols, are silicone surfactants as depicted m the structures m the previous paragraph wherem R^ is -(CH 2 ) n -0-R 5 , wherem R-> is a cationic, anionic, amphoteric, or zwitteπonic moiety Nonhmiting examples of dimethicone copolyols and other silicone surfactants useful as emulsifiers herem mclude polydimethylsiloxane polyether copolymers with pendant polyethylene oxide sidechams, polydimethylsiloxane polyether copolymers with pendant polypropylene oxide sidechams, polydimethylsiloxane polyether copolymers with pendant mixed polyethylene oxide and polypropylene oxide sidechams, polydimethylsiloxane polyether copolymers with pendant mixed poly(ethylene)(propylene)oxιde sidechams, polydimethylsiloxane polyether copolymers with pendant organobetame sidechams, polydimethylsiloxane polyether copolymers with pendant carboxylate sidechams, polydimethylsiloxane polyether copolymers with pendant quaternary ammonium sidechams, and also further modifications of the precedmg copolymers contammg pendant C2-C30 straight, branched, or cyclic alkyl moieties Examples of commercially available dimethicone copolyols useful herem sold by Dow Corning Corporation are Dow Corning® 190, 193, Q2-5220, 2501 Wax, 2-5324 fluid, and 3225C (this later material being sold as a mixture with cyclomethicone) Cetyl dimethicone copolyol is commercially available as a mixture with polyglyceryl-4 isostearate (and) hexyl laurate and is sold under the tradename ABIL® WE-09 (available from Goldschmidt) Cetyl dimethicone copolyol is also commercially available as a mixture with hexyl laurate (and) polyglyceryl-3 oleate (and) cetyl dimethicone and is sold under the tradename ABIL® WS-08 (also available from Goldschnudt) Other nonlimiting examples of dimethicone copolyols also mclude lauryl dimethicone copolyol, dimethicone copolyol acetate, diemethicone copolyol adipate, dimethicone copolyolamine, dimethicone copolyol behenate, dimethicone copolyol butyl ether, dimethicone copolyol hydroxy stearate, dimethicone copolyol isostearate, dimethicone copolyol laurate, dimethicone copolyol methyl ether, dimethicone copolyol phosphate, and dimethicone copolyol stearate See International Cosmetic Ingredient Dictionary, Fifth Edition, 1993, which is incorporated by reference herem in its entirety Dimethicone copolyol emulsifiers useful herein are described, for example, m U.S Patent No 4,960,764, to Figueroa, Jr. et al , issued October 2, 1990, European Patent No. EP 330,369, to SanoGueira, published August 30, 1989, G.H. Dahms, et al , "New Formulation Possibilities Offered by Sihcone Copolyols," Cosmetics & Toiletries, vol 110, pp. 91-100, March 1995; M.E Carlotti et al , "Optimization of W/O-S Emulsions And Study Of The Quantitative Relationships Between Ester Structure And Emulsion Properties," J Dispersion Science And Technology, 13(3), 315-336 (1992), P Hameyer, "Comparative Technological Investigations of Organic and Organosihcone Emulsifiers m Cosmetic Water-m-Oil Emulsion Preparations," HAPPI 28(4), pp. 88-128 (1991), J. Smid-Korbar et al , "Efficiency and usability of silicone surfactants m emulsions," Provisional Communication, International Journal of Cosmetic Science, 12, 135-139 (1990), and D.G Krzysik et al , "A New Silicone Emulsifier For Water-m-Oil Systems," Drug and Cosmetic Industry, vol 146(4) pp 28-81 (April 1990); incorporated by reference herem in their entirety. Among the non-sihcone-containing emulsifiers useful herem are various non-ionic and anionic emulsifying agents such as sugar esters and polyesters, alkoxylated sugar esters and polyesters, C1-C30 fatty acid esters of C1-C30 fatty alcohols, alkoxylated derivatives of C1-C30 fatty acid esters of C1-C30 fatty alcohols, alkoxylated ethers of C1-C30 fatty alcohols, polyglyceryl esters of C1-C30 fatty acids, C1-C30 esters of polyols, C1-C30 ethers of polyols, alkyl phosphates, polyoxyalkylene fatty ether phosphates, fatty acid amides, acyl lactylates, soaps, and mixtures thereof Other suitable emulsifiers are descnbed, for example, m McCutcheon's, Detergents and Emulsifiers. North American Edition (1986), published by Allured Publishing Corporation, U.S Patent No 5,011,681 to Ciotti et al , issued April 30, 1991, U S. Patent No 4,421,769 to Dixon et al , issued December 20, 1983; and U.S Patent No. 3,755,560 to Dickert et al., issued August 28, 1973, tiiese references are incorporated herem by reference m their entirety. Nonlimiting examples of these non-sihcon-containing emulsifiers mclude- polyethylene glycol 20 sorbitan monolaurate (Polysorbate 20), polyethylene glycol 5 soya sterol, Steareth-20, Ceteareth-20, PPG-2 methyl glucose ether distearate, Ceteth-10, Polysorbate 80, cetyl phosphate, potassium cetyl phosphate, diethanolamine cetyl phosphate, Polysorbate 60, glyceryl stearate, PEG- 100 stearate, polyoxyethylene 20 sorbitan tπoleate (Polysorbate 85), sorbitan monolaurate, polyoxyethylene 4 lauryl ether sodium stearate, polyglyceryl-4 isostearate, hexyl laurate, steareth-20, ceteareth-20, PPG-2 methyl glucose ether distearate, ceteth-10, diethanolamine cetyl phosphate, glyceryl stearate, PEG- 100 stearate, and mixtures thereof. b) Oil-in-Water Emulsions Other prefened topical caniers include oil-in-water emulsions, having a continuous aqueous phase and a hydrophobic, water-insoluble phase ("oil phase") dispersed therein. Examples of suitable caniers comprising oil-in-water emulsions are described in U.S. Pat. No. 5,073,371, to Turner, D.J. et al, issued Dec. 17, 1991, and U.S. Pat. No. 5,073,372, to Turner, D.J. et al, issued Dec. 17, 1991, both incorporated herein by reference in their entirety. An especially prefened oil-in- water emulsion, containing a structuring agent, hydrophilic surfactant and water, is described in detail hereinafter. (i) Structuring Agent A prefened oil-in-water emulsion comprises a structuring agent to assist in the formation of a liquid crystalline gel network structure. Concentrations of such structuring agents are from about 1%> to about 20%, preferably from about 1%> to about 10%, more preferably from about 3% to about 9%> by weight of the topical carrier. Suitable structuring agents are those selected from the group consisting of saturated C to C30 fatty alcohols, saturated C j g to C30 fatty alcohols containing from about 1 to about 5 moles of ethylene oxide, saturated C j g to C30 diols, saturated C j g to C30 monoglycerol ethers, saturated C15 to C30 hydroxy fatty acids, and mixtures thereof, having a melting point of at least about 45°C. Prefened structuring agents include stearyl alcohol, cetyl alcohol, behenyl alcohol, stearic acid, palmitic acid, the polyethylene glycol ether of stearyl alcohol having an average of about 1 to about 5 ethylene oxide units, the polyethylene glycol ether of cetyl alcohol having an average of about 1 to about 5 ethylene oxide units, and mixtures thereof. More prefened structuring agents of the present invention are selected from the group consisting of stearyl alcohol, cetyl alcohol, behenyl alcohol, the polyethylene glycol ether of stearyl alcohol having an average of about 2 ethylene oxide units (steareth-2), the polyethylene glycol ether of cetyl alcohol having an average of about 2 ethylene oxide units, and mixtures thereof. Even more prefened structuring agents are selected from the group consisting of stearyl alcohol, cetyl alcohol, behenyl alcohol, steareth-2, and mixtures thereof. Most preferred is steareth-2, available under the tradename of Brij® 72 from ICI Americas. (ii) Hydrophilic surfactant The prefened oil-in-water emulsions comprise from about 0.05%> to about 10%, preferably from about 1% to about 6%, and more preferably from about 1% to about 3% of at least one hydrophilic surfactant which can disperse the hydrophobic materials in the water phase (percentages by weight of the topical canier). The surfactant, at a minimum, must be hydrophilic enough to disperse in water. Suitable surfactants include any of a wide variety of known cationic, anionic, zwitterionic, and amphoteric surfactants. See, McCutcheon's, Detergents and Emulsifiers. North American Edition (1986), published by Allured Publishing Corporation; U.S. Patent 5,011,681; U.S. Patent 4,421,769; and U.S. Patent 3,755,560; these references are incorporated herein by reference in their entirety. The exact surfactant chosen will depend upon the pH of the composition and the other components present. Prefened are cationic surfactants, especially dialkyl quaternary ammonium compounds, examples of which are described in U.S. Patent 5,151,209; U.S. Patent 5,151,210; U.S. Patent 5,120,532; U.S. Patent 4,387,090; U.S. Patent 3,155,591; U.S. Patent 3,929,678; U.S. Patent 3,959,461; McCutcheon's, Detergents & Emulsifiers, (North American edition 1979) M.C. Publishing Co.; and Schwartz, et al. Surface Active Agents, Their Chemistry and Technology. New York: Interscience Publishers, 1949; which descriptions are incorporated herein by reference. The cationic surfactants useful herein include cationic ammonium salts such as those having the formula: R 2 — M— R 3 R . wherein R j , is an alkyl group having from about 12 to about 30 carbon atoms, or an aromatic, aryl or alkaryl group having from about 12 to about 30 carbon atoms; R2, R3, and R4 are independently selected from hydrogen, an alkyl group having from about 1 to about 22 carbon atoms, or aromatic, aryl or alkaryl groups having from about 12 to about 22 carbon atoms; and X is any compatible anion, preferably selected from the group consisting of chloride, bromide, iodide, acetate, phosphate, nitrate, sulfate, methyl sulfate, ethyl sulfate, tosylate, lactate, citrate, glycolate, and mixtures thereof. Additionally, the alkyl groups of R j , R2, R3, and R4 can also contain ester and/or ether linkages, or hydroxy or amino group substituents (e.g., the alkyl groups can contain polyethylene glycol and polypropylene glycol moieties). More preferably, R j is an alkyl group having from about 12 to about 22 carbon atoms; R2 is selected from H or an alkyl group having from about 1 to about 22 carbon atoms; R3 and R4 are independently selected from H or an alkyl group having from about 1 to about 3 carbon atoms; and X is as described previously. Most preferably, Ri is an alkyl group having from about 12 to about 22 carbon atoms; R2, R3, and R4 are selected from H or an alkyl group having from about 1 to about 3 carbon atoms; and X is as described previously. Alternatively, other useful cationic emulsifiers include amino-amides, wherein in the above structure R j is alternatively R5CONH-(CH2) n , wherein R5 is an alkyl group having from about 12 to about 22 carbon atoms, and n is an integer from about 2 to about 6, more preferably from about 2 to about 4, and most preferably from about 2 to about 3. Nonlimiting examples of these cationic emulsifiers include stearamidopropyl PG-dimonium chloride phosphate, behenamidopropyl PG dimonium chloride, stearamidopropyl ethyldimonium ethosulfate, stearamidopropyl dimethyl (myπstyl acetate) ammonium chloride, stearamidopropyl dimethyl cetearyl ammonium tosylate, stearamidopropyl dimethyl ammonium chloride, stearamidopropyl dimethyl ammonium lactate, and mixtures thereof Especially prefened is behenamidopropyl PG dimonium chloride Nonhmiting examples of quaternary ammonium salt cationic surfactants include those selected from the group consisting of cetyl ammonium chloride, cetyl ammonium bromide, lauryl ammonium chloride, lauryl ammonium bromide, stearyl ammonium chloride, stearyl ammonium bromide, cetyl dimethyl ammonium chloride, cetyl dimethyl ammonium bromide, lauryl dimethyl ammonium chloride, lauryl dimethyl ammonium bromide, stearyl dimethyl ammonium chloride, stearyl dimethyl ammonium bromide, cetyl tπmethyl ammonium chlonde, cetyl tπmethyl ammonium brormde, lauryl tnmethyl ammonium chloride, lauryl tπmethyl ammonium bromide, stearyl tnmethyl ammonium chloride, stearyl tnmethyl ammonium bromide, lauryl dimethyl ammonium chloride, stearyl dimethyl cetyl ditallow dimethyl ammonium chlonde, dicetyl ammonium chloride, dicetyl ammonium bromide, dilauryl ammonium chloride, dilauryl ammonium bromide, distearyl ammonium chlonde, distearyl ammonium bromide, dicetyl methyl ammonium chloride, dicetyl methyl ammonium bromide, dilauryl methyl ammonium chloride, dilauryl methyl ammonium bromide, distearyl methyl ammonium chloride, distearyl methyl ammonium brormde, and mixtures thereof Additional quaternary ammonium salts mclude those wherem the C j 2 t0 C30 alkyl carbon cham is denved from a tallow fatty acid or from a coconut fatty acid The term "tallow" refers to an alkyl group derived from tallow fatty acids (usually hydrogenated tallow fatty acids), which generally have mixtures of alkyl chams in the C j g to C j g range The term "coconut" refers to an alkyl group denved from a coconut fatty acid, which generally have mixtures of alkyl chams m the C j 2 to C j 4 range Examples of quaternary ammonium salts denved from these tallow and coconut sources mclude ditallow dimethyl ammonium chloride, ditallow dimethyl ammonium methyl sulfate, dι(hydrogenated tallow) dimethyl ammonium chloride, dι(hydrogenated tallow) dimethyl ammonium acetate, ditallow dipropyl ammonium phosphate, ditallow dimethyl ammonium nitrate, dι(coconutalkyl)dιmethyl ammonium chlonde, dι(coconutalkyl)dιmethyl ammonium bromide, tallow ammonium chlonde, coconut ammonium chlonde, stearamidopropyl PG-dimonium chlonde phosphate, stearamidopropyl ethyldimomum ethosulfate, stearamidopropyl dimethyl (mynstyl acetate) ammonium chlonde, stearamidopropyl dimethyl cetearyl ammonium tosylate, stearamidopropyl dimethyl ammonium chloride, stearamidopropyl dimethyl ammonium lactate, and mixtures thereof An example of a quaternary ammonium compound havmg an alkyl group with an ester linkage is ditallowyl oxyethyl dimethyl ammonium chlonde More prefened cationic surfactants are those selected from the group consisting of behenamidopropyl PG dimonium chloride, dilauryl dimethyl ammonium chloride, distearyl dimethyl ammonium chloride, dimyπstyl dimethyl ammonium chlonde, dipalmityl dimethyl ammonium chlonde, distearyl dimethyl ammonium chlonde, stearamidopropyl PG-dimomum chlonde phosphate, stearamidopropyl ethyldiammonium ethosulfate, stearamidopropyl dimethyl (mynstyl acetate) ammonium chloride, stearamidopropyl dimethyl cetearyl ammonium tosylate, stearamidopropyl dimethyl ammonium chloride, stearamidopropyl dimethyl ammonium lactate, and mixtures thereof. Most prefened cationic surfactants are those selected from the group consisting of behenamidopropyl PG dimonium chloride, dilauryl dimethyl ammonium chloride, distearyl dimethyl ammonium chloride, dimyristyl dimethyl ammonium chloride, dipalmityl dimethyl ammonium chloride, and mixtures thereof. A prefened combination of cationic surfactant and structuring agent is behenamidopropyl PG dimonium chloride and/or behenyl alcohol, wherein the ratio is preferably optimized to maintained to enhance physical and chemical stability, especially when such a combination contains ionic and/or highly polar solvents. This combination is especially useful for delivery of sunscreening agents such as zinc oxide and octyl methoxycinnamate. A wide variety of anionic surfactants are also useful herein. See, e.g., U.S. Patent No. 3,929,678, to Laughlin et al, issued December 30, 1975, which is incorporated herein by reference in its entirety. Nonlimiting examples of anionic surfactants include the alkoyl isethionates, and the alkyl and alkyl ether sulfates. The alkoyl isethionates typically have the formula RCO-OCH CH SO M wherein R is alkyl or alkenyl of from about 10 to about 30 carbon atoms, and M is a water-soluble cation such as ammonium, sodium, potassium and triethanolamine. Nonlimiting examples of these isethionates include those alkoyl isethionates selected from the group consisting of ammonium cocoyl isethionate, sodium cocoyl isethionate, sodium lauroyl isethionate, sodium stearoyl isethionate, and mixtures thereof. The alkyl and alkyl ether sulfates typically have the respective formulae ROSO-M and RO(C H O) SO M, wherein R is alkyl or alkenyl of from about 10 to about 30 carbon atoms, x is from about 1 to about 10, and M is a water-soluble cation such as ammonium, sodium, potassium and triethanolamine. Another suitable class of anionic surfactants are the water-soluble salts of the organic, sulfuric acid reaction products of the general formula: R -SO -M wherein R is chosen from the group consisting of a straight or branched chain, saturated aliphatic hydrocarbon radical having from about 8 to about 24, preferably about 10 to about 16, carbon atoms; and M is a cation. Still other anionic synthetic surfactants include the class designated as succinamates, olefm sulfonates having about 12 to about 24 carbon atoms, and β-alkyloxy alkane sulfonates. Examples of these materials are sodium lauryl sulfate and ammonium lauryl sulfate. Other anionic materials useful herein are soaps (i.e. alkali metal salts, e.g., sodium or potassium salts) of fatty acids, typically having from about 8 to about 24 carbon atoms, preferably from about 10 to about 20 carbon atoms. The fatty acids used in making the soaps can be obtained from natural sources such as, for instance, plant or animal-derived glycerides (e.g., palm oil, coconut oil, soybean oil, castor oil, tallow, lard, etc ) The fatty acids can also be synthetically prepared Soaps are described in more detail m U S Patent No 4,557,853, cited above Amphoteric and zwitteπonic surfactants are also useful herem Examples of amphoteric and zwitteπonic surfactants which can be used m the compositions of the present invention are those which are broadly described as derivatives of aliphatic secondary and tertiary amines m which the aliphatic radical can be straight or branched chain and wherem one of the aliphatic substituents contains from about 8 to about 22 carbon atoms (preferably Cg - C j g) and one contams an anionic water solubilizing group, e g , carboxy, sulfonate, sulfate, phosphate, or phosphonate Examples are alkyl immo acetates, and lminodialkanoates and aminoalkanoates of the formulas RN[CH 2 ) m C0 2 M] 2 and RNH(CH 2 ) m CO-M wherein m is from 1 to 4, R is a C -C 22 alkyl or alkenyl, and M is H, alkali metal, alkaline earth metal ammonium, or alkanolammonium Also included are lmidazolmium and ammonium derivatives Specific examples of suitable amphoteric surfactants mclude sodium 3-dodecyl-amιnopropιonate, sodium 3-dodecylammopropane sulfonate, N-alkyltauπnes such as the one prepared by reacting dodecylamine with sodium isethionate accordmg to the teaching of U S Patent 2,658,072 which is incorporated herein by reference m its entirety, N-higher alkyl aspartic acids such as those produced accordmg to the teaching of U S Patent 2,438,091 which is incorporated herem by reference m its entirety, and the products sold under the trade name "Mrranol" and described m U S Patent 2,528,378, which is incorporated herem by reference in its entirety Other examples of useful amphoteπcs mclude phosphates, such as coamidopropyl PG-dimomum chloride phosphate (commercially available as Monaquat PTC, from Mona Corp ) Also useful herein as amphoteric or zwitteπonic surfactants are the betames Examples of betames mclude the higher alkyl betames, such as coco dimethyl carboxymethyl betame, lauryl dimethyl carboxymethyl betame, lauryl dimethyl alphacarboxyethyl betame, cetyl dimethyl carboxymethyl betame, cetyl dimethyl betame (available as Lonzarne 16SP from Lonza Corp ), lauryl bιs-(2-hydroxyethyl) carboxymethyl betame, stearyl bιs-(2-hydroxypropyl) carboxymethyl betame, oleyl dimethyl gamma-carboxypropyl betame, lauryl bιs-(2-hydroxypropyl)alpha-carboxyethyl betame, coco dimethyl sulfopropyl betame, stearyl dimethyl sulfopropyl betame, lauryl dimethyl sulfoethyl betame, lauryl bιs-(2-hydroxyethyl) sulfopropyl betame, and amidobetaines and amidosulfobetaines (wherem the RCONH(CH ) radical is attached to the nitrogen atom of the betame), oleyl betame (available as amphotenc Velvetex OLB-50 from Henkel), and cocamidopropyl betame (available as Velvetex BK-35 and BA-35 from Henkel) Other useful amphoteric and zwitteπomc surfactants mclude the sultames and hydroxysultames such as cocamidopropyl hydroxysultaine (available as Mrrataine CBS from Rhone-Poulenc), and the alkanoyl sarcosmates conespondmg to the formula RCON(CH )CH CH CO M wherem R is alkyl or alkenyl of about 10 to about 20 carbon atoms, and M is a water-soluble cation such as ammonium, sodium, potassium and tπalkanolamine (e g , triethanolamine), a prefened example of which is sodium lauroyl sarcosmate (m) Water The prefened oil-in-water emulsion comprises from about 25%> to about 98%>, preferably from about 65%o to about 95%>, more preferably from about 70%> to about 90%> water by weight of the topical earner The hydrophobic phase is dispersed m the continuous aqueous phase The hydrophobic phase may contain water insoluble or partially soluble materials such as are known m the art, including but not limited to the silicones described herem in reference to sihcone-in-water emulsions, and other oils and hpids such as described above in reference to emulsions The topical compositions of the subject invention, mcludmg but not limited to lotions and creams, may compnse a dermatologically acceptable emollient Such compositions preferably contam from about 2% to about 50% of the emollient As used herein, "emollient" refers to a material useful for the prevention or relief of dryness, as well as for the protection of the skm A wide vanety of suitable emollients are known and may be used herem Sagarin, Cosmetics, Science and Technology, 2nd Edition, Vol 1, pp 32-43 (1972), incorporated herem by reference, contams numerous examples of materials suitable as an emolhent A prefened emollient is glycerin Glycerin is preferably used m an amount of from or about 0 001 to or about 20%, more preferably from or about 0 01 to or about 10%>, most preferably from or about 0 1 to or about 5%, e g , 3%> Lotions and creams accordmg to the present invention generally comprise a solution earner system and one or more emollients Lotions typically comprise from about 1% to about 20%, preferably from about 5% to about 10%>, of emollient, from about 50% to about 90%>, preferably from about 60%> to about 80%>, water, and dehydroacetic acid m the above described amounts A cream typically comprises from about 5% to about 50%>, preferably from about 10%> to about 20%>, of emollient, from about 45%> to about 85%o, preferably from about 50%> to about 75%, water, and dehydroacetic acid m the above described amounts Ointments of the present invention may comprise a simple earner base of annual or vegetable oils or semi-solid hydrocarbons (oleaginous), absorption ointment bases which absorb water to form emulsions, or water soluble earners, e g , a water soluble solution earner Ointments may further compnse a thickening agent, such as desenbed m Sagarm, Cosmetics. Science and Technology, 2nd Edition, Vol 1, pp 72-73 (1972), incorporated herem by reference, and/or an emollient For example, an ointment may comprise from about 2% to about 10% of an emollient, from about 0 1%> to about 2% of a thickenmg agent, and dehydroacetic acid m the above described amount Compositions of this mvention useful for cleansing ("cleansers") are formulated with a suitable earner, e g , as described above, and preferably contam, m addition to dehydroacetic acid m the above described amounts, from about 1%> to about 90%>, more preferably from about 5% to about 10%), of a dermatologically acceptable surfactant The surfactant is suitably selected from amomc, nonionic, zwitteπonic, amphoteric and ampholytic surfactants, as well as mixtures of these surfactants Such surfactants are well known to those skilled m the detergency art Nonlimiting examples of possible surfactants mclude ιsoceteth-20, sodium methyl cocoyl taurate, sodium methyl oleoyl taurate, and sodium lauryl sulfate See U S Patent No 4,800,197, to Kowcz et al , issued January 24, 1989, which is incorporated herein by reference m its entirety, for exemplary surfactants useful herein Examples of a broad variety of additional surfactants useful herem are described m McCutcheon's Detergents and Emulsifiers, North American Edition (1986), published by Allured Publishing Corporation, which is incorporated herem by reference in its entirety The cleansmg compositions can optionally contam, at their art-established levels, other materials which are conventionally used m cleansmg compositions The physical form of the cleansmg compositions is not critical The compositions can be, for example, formulated as toilet bars, liquids, shampoos, bath gels, hair conditioners, hair tonics, pastes, or mousses Toilet bars are most prefened smce this is the form of cleansmg agent most commonly used to wash the skm Rinse-off cleansmg compositions, such as shampoos, require a delivery system adequate to deposit sufficient levels of actives on the skm and scalp A prefened delivery system involves the use of insoluble complexes For a more complete disclosure of such delivery systems, see U S Patent 4,835,148, Barford et al , issued May 30, 1989, incorporated herem by reference in its entirety As used herem, the term "foundation" refers to a liquid, semi-liquid, semi-solid, or solid skm cosmetic which mcludes, but is not limited to lotions, creams, gels, pastes, cakes, and the like Typically the foundation is used over a large area of the skm, such as over the face, to provide a particular look Foundations are typically used to provide an adherent base for color cosmetics such as rouge, blusher, powder and the like, and tend to hide skm imperfections and impart a smooth, even appearance to the skm Foundations of the present mvention mclude a dermatologically acceptable earner for dehydroacetic acid and may mclude conventional mgredients such as oils, colorants, pigments, emollients, fragrances, waxes, stabilizers, and the like Exemplary earners and such other mgredients which are suitable for use herein are described, for example, m copendmg patent application Senal No 08/430,961, filed on April 28, 1995 m the names of Marcia L Canter, Bram D Barford, and Bnan D Hofrichter, and U K Patent Application GB 2274585-A, published on Jan 23, 1993, both incorporated herem by reference The compositions of the present mvention are preferably formulated to have a pH of 10 5 or below The pH values of these compositions preferably range from about 2 to about 10 5, more preferably from about 3 to about 8, even more preferably from about 4 to about 7, and also from about 4 5 to about 5 5 IV Optional Ingredients The topical compositions of the present invention may comprise a wide variety of optional components (e.g., ingredients conventionally used in the art of skin care compositions, including but not limited to preservatives, preservative enhancers, and actives in addition to the primary actives), provided that such optional components are physically and chemically compatible with the essential components described herein, and do not unduly impair stability, efficacy or other use benefits associated with the compositions of the present invention. Any optional ingredients should be compatible with the dehydroacetic acid such that its activity does not decrease unacceptably, preferably not to any significant extent, over a useful period (preferably at least about six months under normal storage conditions). Optional components may be dispersed, dissolved or the like in the canier of the present compositions. The compositions of the subject invention may optionally comprise other actives capable of functioning in different ways to enhance the benefits of the dehydroacetic acid and the ancillary actives and/or to provide other benefits. Optional components include aesthetic agents and other active agents. For example, the compositions may include absorbents, abrasives, anticaking agents, antifoaming agents, antimicrobial agents, binders, biological additives, buffering agents, bulking agents, chemical additives, cosmetic biocides, denaturants, cosmetic astringents, drug astringents, external analgesics, film formers, humectants, opacifying agents, fragrances, pigments, colorings, essential oils, skin sensates, emollients, skin soothing agents, skin healing agents, pH adjusters, plasticizers, preservatives, preservative enhancers, propellants, reducing agents, additional skin- conditioning agents, skin penetration enhancing agents, skin protectants, solvents, suspending agents, emulsifiers, thickening agents, solubilizing agents, sunscreens, sunblocks, ultraviolet light absorbers or scattering agents, sunless tanning agents, antioxidants and or radical scavengers, chelating agents, sequestrants, anti-acne agents, anti-inflammatory agents, anti-androgens, depilation agents, desquamation agents/exfoliants, organic hydroxy acids, vitamins and derivatives thereof, and natural extracts. Such other materials are known in the art. Nonexclusive examples of such materials are described in Harry's Cosmeticology, 7th Ed, Harry & Wilkinson (Hill Publishers, London 1982); in Pharmaceutical Dosage Forms- Disperse Systems; Lieberman, Rieger & Banker, Vols. 1 (1988) & 2 (1989); Marcel Decker, Inc.; in The Chemistry and Manufacture of Cosmetics, 2nd. Ed, deNavane (Van Nostrand 1962-1965); and in The Handbook of Cosmetic Science and Technology. 1st Ed.. Knowlton & Pearce (Elsevier 1993). Specific examples of optional components include the following. The active ingredients useful herein are categorized by their cosmetic and/or therapeutic benefit or their postulated mode of action. However, it is to be understood that the active ingredients useful herein can in some instances provide more than one cosmetic and/or therapeutic benefit or operate via more than one mode of action. Therefore, classifications herein are made for the sake of convenience and are not intended to limit the active ingredient to that particular application or applications listed. A. Sunscreens and Sunblocks Exposure to ultraviolet light can result in significant skm damage, as well as, excessive scaling and texture changes of the stratum corneum Therefore, the compositions of the subject mvention preferably contain a sunscreen or sunblock Suitable sunscreens or sunblocks may be organic or inorganic A wide variety of conventional sunscreenmg agents are suitable for use herem Sagarm, et al , at Chapter VIII, pages 189 et seq , of Cosmetics Science and Technology (1972), discloses numerous suitable agents, and is incorporated herein by reference Specific suitable sunscreenmg agents include, for example p-aminobenzoic acid, its salts and its derivatives (ethyl, isobutyl, glyceryl esters, p-dimethylaminobenzoic acid), anthramlates (l e , o-amino-benzoates, methyl, menthyl, phenyl, benzyl, phenylethyl, linalyl, terpinyl, and cyclohexenyl esters), sahcylates (amyl, phenyl, octyl, benzyl, menthyl, glyceryl, and di-pro-pyleneglycol esters), cinnanuc acid derivatives (menthyl and benzyl esters, a-phenyl cinnamomtπle, butyl cinnamoyl pyruvate), dihydroxycinnamic acid derivatives (umbelhferone, methylumbelhferone, methylaceto-umbelliferone), tnhydroxy- cinnamic acid derivatives (esculetin, methylesculetin, daphnetm, and the glucosides, esculm and daphnin), hydrocarbons (diphenylbutadiene, stilbene), dibenzalacetone and benzalacetophenone, naphtholsulfonates (sodium salts of 2-naphthol-3,6-dιsulfonιc and of 2-naphthol-6,8-dιsulfonιc acids), di-hydroxynaphthoic acid and its salts, o- and p-hydroxybiphenyldisulfonates, coumann derivatives (7-hydroxy, 7-methyl, 3-phenyl), diazoles (2-acetyl-3-bromomdazole, phenyl benzoxazole, methyl naphthoxazole, various aryl benzothiazoles), quinine salts (bisulfate, sulfate, chloride, oleate, and tannate), qumolme derivatives (8-hydroxyqurnolιne salts, 2-phenylqumolme), hydroxy- or methoxy-substituted benzophenones, uric and violuπc acids, tannic acid and its derivatives (e g , hexaethylether), (butyl carbotol) (6-propyl piperonyl) ether, hydroquinone, benzophenones (oxybenzene, suhsobenzone, dioxybenzone, benzoresorcmol, 2,2',4,4'- tetrahydroxybenzophenone, 2,2'-dιhydroxy-4,4'-dιmethoxybenzophenone, octabenzone, 4- lsopropyldibenzoylmethane, butylmethoxydibenzoylmethane, etocrylene, octocrylene, [3-(4'- methylbenzyhdene bornan-2-one) and 4-ιsopropyl-dι-benzoylmethane Of these, 2-ethylhexyl-p-methoxycιnnamate (commercially available as PARSOL MCX), 4,4'-t-butyl methoxydibenzoyl-methane (commercially available as PARSOL 1789), 2-hydroxy-4- metiioxybenzophenone, octyldimethyl-p-ammobenzoic acid, digalloyltnoleate, 2,2-dιhydroxy-4- methoxybenzophenone, ethyl-4-(bιs(hydroxy-propyl))ammobenzoate, 2-ethylhexyl-2-cyano-3 ,3 - diphenylacrylate, 2-ethylhexyl-sahcylate, glyceryl-p-aminobenzoate, 3,3,5-tn- methylcyclohexylsalicylate, methylanthramlate, p-dimethyl-ammobenzoic acid or aminobenzoate, 2- ethylhexyl-p-dimethyl-amino-benzoate, 2-phenylbenzιmιdazole-5-sulfonιc acid, 2-(p- dιmethylammophenyl)-5-sulfonιcbenzoxazoιc acid, octocrylene and mixtures of these compounds, are prefened More prefened organic sunscreens useful in the compositions useful m the subject invention are 2-ethyιhexyl-p-methoxycιnnamate, butylmethoxydibenzoyl-methane, 2-hydroxy-4- methoxybenzo-phenone, 2-phenylbenzιmιdazole-5-sulfomc acid, octyldimethyl-p-ammobenzoic acid, octocrylene and mixtures thereof Also particularly useful m the compositions are sunscreens such as those disclosed m U S Patent No 4,937,370 issued to Sabatelh on June 26, 1990, and U S Patent No 4,999,186 issued to Sabatelh & Spirnak on March 12, 1991, both of which are incorporated herem by reference The sunscreenmg agents disclosed therein have, in a smgle molecule, two distmct chromophore moieties which exhibit different ultra-violet radiation absorption spectra One of the chromophore moieties absorbs predominantly in the UVB radiation range and the other absorbs strongly in the UVA radiation range Prefened members of this class of sunscreenmg agents are 4-N,N-(2-ethylhexyl)methyl- aminobenzoic acid ester of 2,4-dιhydroxybenzophenone, N,N-dι-(2-ethylhexyl)-4-aιmnobenzoιc acid ester with 4-hydroxydιbenzoylmethane, 4-N,N-(2-ethylhexyl)methyl-amιnobenzoιc acid ester with 4- hydroxydibenzoylmethane, 4-N,N-(2-ethylhexyl)methyl-amιnobenzoιc acid ester of 2-hydroxy-4-(2- hydroxyethoxy)benzophenone, 4-N,N-(2-ethylhexyl)-methylamιnobenzoιc acid ester of 4-(2- hydroxyethoxy)dιbenzoylmethane, N,N-dι-(2-ethylhexyl)-4-amιnobenzoιc acid ester of 2-hydroxy-4- (2-hydroxyethoxy)benzophenone, and N,N-dι-(2-ethylhexyl)-4-ammobenzoιc acid ester of 4-(2- hydroxyethoxy)dιbenzoylmethane and mixtures thereof Suitable morganic sunscreens or sunblocks include metal oxides, e g , zmc oxide and titanium dioxide For example, the use of a titanium dioxide m topical sunscreen compositions that is applicable to the present invention is described m copendmg application Serial No 08/448,942, filed on May 24, 1995, m the names of Jiang Yue, Lisa R Dew and Donald L Bissett, incorporated herem by reference Especially prefened sunscreens or sunblocks mclude the metal oxides such as zmc oxide and titanium dioxide, butylmethoxydibenzoylmethane, 2-ethylhexyl-p-methoxycιnnamate, phenyl benzmudazole sulfonic acid, and octocrylene A safe and effective amount of the sunscreen or sunblock is used, typically from about 1%> to about 20%), more typically from about 2%> to about 10% Exact amounts will vary dependmg upon the sunscreen chosen and the desired Sun Protection Factor (SPF) An agent may also be added to any of the compositions useful m the subject mvention to improve the skm substantivity of those compositions, particularly to enhance their resistance to bemg washed off by water, or rubbed off A prefened agent which will provide this benefit is a copolymer of ethylene and acrylic acid Compositions comprising this copolymer are disclosed m U S Patent 4,663,157, Brock, issued May 5, 1987, which is incorporated herem by reference B. Anti-Oxidants/Radical Scavengers Prefened compositions of the subject mvention mclude an anti-oxidant/radical scavenger as an active m addition to the primary active agents The anti-oxidant/radical scavenger is especially useful for providing protection against UV radiation which can cause mcreased scalmg or texture changes in the stratum corneum and against other environmental agents which can cause skin damage. In addition, anti-oxidants are useful to reduce inflammation associated with acne, as discussed hereinbefore. A safe and effective amount of an anti-oxidant/radical scavenger may be added to the compositions of the subject invention, preferably from about 0.1% to about 10%, more preferably from about 1% to about 5%, of the composition. Anti-oxidants/radical scavengers such as ascorbic acid (vitamin C) and its salts, ascorbyl esters of fatty acids, ascorbic acid derivatives (e.g., magnesium ascorbyl phosphate), tocopherol (vitamin E), tocopherol sorbate, other esters of tocopherol (e.g., acetate, succinate, linoleate), butylated hydroxy benzoic acids and their salts, 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (commercially available under the tradename Trolox^-), gallic acid and its alkyl esters, especially propyl gallate, uric acid and its salts and alkyl esters, sorbic acid and its salts, amines (e.g., N,N-diethylhydroxylamine, amino-guanidine), sulfhydryl compounds (e.g., glutathione), dihydroxy fumaric acid and its salts, lycine pidolate, arginine pilolate, nordihydroguaiaretic acid, bioflavonoids, lysine, methionine, proline, superoxide dismutase, silymarin, tea extracts (e.g, green tea extracts), grape skin/seed extracts, melanin, and rosemary extracts may be used. Prefened anti- oxidants/radical scavengers are selected from tocopherol sorbate and other esters of tocopherol, more preferably tocopherol sorbate. For example, the use of tocopherol sorbate in topical compositions and applicable to the present invention is described in U.S. Patent No. 4,847,071, issued on July 11, 1989 to Donald L. Bissett, Rodney D. Bush and Ranjit Chatterjee, incorporated herein by reference. C. Chelators As used herein, "chelating agent" means an active agent capable of removing a metal ion from a system by forming a complex so that the metal ion cannot readily participate in or catalyze chemical reactions. The inclusion of a chelating agent is especially useful for providing protection against UV radiation which can contribute to excessive scaling or skin texture changes and against other environmental agents which can cause skin damage. A safe and effective amount of a chelating agent may be added to the compositions of the subject invention, preferably from about 0.1% to about 10%, more preferably from about 1%> to about 5%, of the composition. Exemplary chelators that are useful herein are disclosed in U.S. Patent No. 5,487,884, issued 1/30/96 to Bissett et al.; International Publication No. 91/16035, Bush et al, published 10/31/95; and International Publication No. 91/16034, Bush et al, published 10/31/95; all incorporated herein by reference. Prefened chelators useful in compositions of the subject invention are furildioxime and derivatives thereof. D. Organic Hydroxy Acids and Keto Acids Compositions of the present invention preferably comprise an organic hydroxy acid and/or a keto acid for providing benefits in regulating skin condition, especially in therapeutically regulating signs of skin aging, more especially wrinkles, fine lines, and pores. Suitable hydroxy acids include C j - Ci g hydroxy acids, preferably Cg or below The hydroxy acids can be substituted or unsubstituted, straight chain, branched cham or cyclic (preferably straight cham), and saturated or unsaturated (mono- or poly- unsaturated) (preferably saturated) Non-limiting examples of suitable hydroxy acids mclude glycolic acid, lactic acid, salicylic acid, 5 octanoyl salicylic acid, hydroxyoctanoic acid, hydroxycaprylic acid, and lanolin fatty acids A nonlimiting example of a keto acid is pyruvic acid Prefened concentrations of the organic hydroxy and/or keto acid range from about 0 1% to about 10%>, more preferably from about 0 2%> to about 5%>, also preferably from about 0 5%> to about 2% Lactic acid, salicylic acid, and pyruvic acid are prefened The organic hydroxy acids enhance the skin appearance benefits of the present mvention For example, the organic hydroxy acids tend to improve the texture of the skm E. Desquamation Agents/Exfoliants A safe and effective amount of a desquamation agent is preferably added to the compositions of the subject invention, more preferably from about 0 1% to about 10%, even more preferably from about 0 2% to about 5%, also preferably from about 0 5% to about 4% of the composition Desquamation agents enhance the skm appearance benefits of the present mvention For example, the desquamation agents tend to improve the texture of the skm (e g , smoothness) A variety of desquamation agents are known in the art and are suitable for use herem, mcludmg but not limited to the organic hydroxy agents described above One desquamation system that is suitable for use herein comprises sulfhydryl compounds and zwitteπonic surfactants and is descnbed m copending application Serial No 08/480,632, filed on June 7, 1995 in the name of Donald L Bissett, conespondmg to PCT Application No U S 95/08136, filed 6/29/95, each incorporated herem by reference Another desquamation system that is suitable for use herem compnses salicylic acid and zwitteπomc surfactants and is descnbed m copendmg patent application Senal No 08/554,944, filed on November 13, 1995 as a continuation of Serial No 08/209,401, filed on March 9, 1994 m the name of Bissett, conespondmg to PCT Application No 94/12745, filed 11/4/94, published 5/18/95, each incorporated herem by reference Zwittenonic surfactants such as described m these applications are also useful as desquamatory agents herem, with cetyl betame bemg particularly prefened F. Depilation Agents The compositions of the present mvention may mclude a safe and effective amount of a depilation agent When used, the composition preferably contams from about 0 1% to about 10%, more preferably from about 0 2%> to about 5%>, also preferably from about 0 5%> to about 2%> of depilation agent A depilation agent prefened for use herem comprises a sulfhydryl compound, e g , N-acetyl-L-cysteine The use of such depilation agents is described in more detail in copendmg application Senal No 08/479,878, filed on June 7, 1995, m the name of Greg G Hillebrand and Vladimir Gartstein, conespondmg to PCT Application No U S 95/07311, filed 6/8/95, each incorporated herem by reference G. Skin Lightening Agents The compositions of the present invention may comprise a skm lightening agent When used, the compositions preferably comprise from about 0 1%> to about 10%>, more preferably from about 0 2% to about 5%, also preferably from about 0 5% to about 2%, of a skm lightening agent Suitable skm lightening agents mclude those known m the art, mcludmg kojic acid, arbutm, macmamide, ascorbic acid and derivatives thereof, e g , magnesium ascorbyl phosphate Skm lightening agents suitable for use herem also mclude those described m copendmg patent application Serial No 08/479,935, filed on June 7, 1995 m the name of Hillebrand, conespondmg to PCT Application No U S 95/07432, filed 6/12/95, and copendmg patent application Serial No 08/390,152, filed on February 24, 1995 in the names of Kalla L Kvalnes, Mitchell A DeLong, Barton J Bradbury, Curtis B Motley, and John D Carter, conespondmg to PCT Application No U S 95/02809, filed 3/1/95, published 9/8/95, all incorporated herem by reference H. Zinc Salts When a vitamm B3 compound is mcluded the present composition, the compositions of the present invention may further comprise a zinc salt Zmc salts are especially prefened where the composition contams a sulfhydryl compound, e g , N-acetyl-L-cysteine Witiiout mtendmg to be limited or bound by theory, it is believed that the zmc salt acts as a chelating agent capable of complexmg with the sulfhydryl compound prior to topical application, stabilizes the sulfhydryl compound and/or controls odor associated with the sulfhydryl compound Concentrations of the zmc salt can range from about 0 001% to about 10%, more preferably from about 0 01% to about 5%, most preferably from about 0 1% to about 0 5% by weight of the composition Prefened zinc salts mclude zmc acetate, zmc acetate hydrates such as zmc acetate-2-water, zmc alummum oxide complexes such as gahnite, zmc diamine, zmc antimonide, zmc bromate hydrates such as zinc bromate-6-water, zinc bromide, zmc carbonates such as zmcspar and smithsomte, zmc chlorate hydrates such as zmc chlorate-4-water, zmc chlonde, zmc diamine dichloπde, zmc citrate, zmc chromate, zmc dichromate, zmc diphosphate, zmc hexacyanofluonde fenate (II), zmc fluoride, zmc fluoride hydrates such as zmc fluonde-4-water, zmc formate, zmc formate hydrates such as zmc formate-2-water, zmc hydroxide, zmc lodate, zmc lodate hydrates such as zmc ιodate-2-water, zmc iodide, zmc iron oxide complexes, zmc nitrate hydrates such as zmc nιtrate-6-water, zmc nitnde, zinc oxalate hydrates such as zmc oxalate-2-water, zmc oxides such as zmcite, zmc perchlorate hydrates such as zmc perchlorate-6-water, zmc permanganate hydrates such as zmc permanganate-6-water, zinc peroxide, zmc >-phenolsulfonate hydrates such as zmc p- phenosulfonate-8-water, zinc phosphate, zmc phosphate hydrates such as zmc phosphate-4-water, zmc phosphide, zmc propionate, zmc selenate hydrates such as zmc selenate-5-water, zmc selenide, zmc silicates such as zmc silicate (2) and zinc silicate (4), zmc silicon oxide water complexes such as hemimorphite, zmc hexafluorosihcate hydrates such as zmc hexafluorosιlιcate-6-water, zmc stearate, zmc sulfate, zinc sulfate hydrates such as zmc sulfate-7-water, zmc sulfide, zmc sulfite hydrates such as zmc sulfite-2-water, zmc telluπde, zmc thiocyanate, zinc (II) salts of N-acetyl L-cysteme, and mixtures thereof Especially prefened zmc salts include zinc citrate, zmc oxide, zmc chloride, zmc acetate, zmc stearate, zmc sulfate, and mixtures thereof Zinc citrate is especially prefened I. Humectants. Moisturizers, and Skin Conditioners The compositions of the present invention may further comprise a humectant, moisturizing agent or other skin conditioning agent A variety of these materials can be employed and each can be present at a level of from or about 0 1% to or about 20%, more preferably from or about 1% to or about 10%), and most preferably from or about 2% to or about 5%o These materials mclude guamdine (e g , urea guanidrne betame), glycohc acid and glycolate salts (e g ammonium and quaternary alkyl ammonium), lactic acid and lactate salts (e g ammonium and quaternary alkyl ammonium), aloe vera in any of its variety of forms (e g , aloe vera gel), polyhydroxy alcohols such as sorbitol, glycerol, hexanetπol, propylene glycol, butylene glycol, hexylene glycol and the like, polyethylene glycols, sugars and starches, sugar and starch derivatives (e g , alkoxylated glucose), hyaluromc acid, lactamide monoethanolamine, acetamide monoethanolamme, and mixtures thereof Also useful herein are the propoxylated glycerols descnbed in U S Patent No 4,976,953, which is description is incorporated herem by reference Also useful are vanous C1-C30 monoesters and polyesters of sugars and related matenals These esters are derived from a sugar or polyol moiety and one or more carboxyhc acid moieties Depending on the constituent acid and sugar, these esters can be in either liquid or solid form at room temperature Examples of liquid esters mclude glucose tetraoleate, the glucose tetraesters of soybean oil fatty acids (unsaturated), the mannose tetraesters of mixed soybean oil fatty acids, the galactose tetraesters of oleic acid, the arabinose tetraesters of hnoleic acid, xylose tetralinoleate, galactose pentaoleate, sorbitol tetraoleate, the sorbitol hexaesters of unsaturated soybean oil fatty acids, xylitol pentaoleate, sucrose tetraoleate, sucrose pentaoletate, sucrose hexaoleate, sucrose hepatoleate, sucrose octaoleate, and mixtures thereof Examples of solid esters mclude sorbitol hexaester m which the carboxyhc acid ester moieties are palmitoleate and arachidate m a 1 2 molar ratio, the octaester of raffinose in which the carboxyhc acid ester moieties are lmoleate and behenate m a 1 3 molar ratio, the heptaester of maltose wherem the esteπfying carboxyhc acid moieties are sunflower seed oil fatty acids and hgnocerate m a 3 4 molar ratio, the octaester of sucrose wherem the esteπfying carboxyhc acid moieties are oleate and behenate m a 2 6 molar ratio, and the octaester of sucrose wherem the esteπfying carboxyhc acid moieties are laurate, lmoleate and behenate m a 1 3 4 molar ratio A prefened solid material is sucrose polyester in which the degree of esteπfication is 7-8, and in which the fatty acid moieties are C18 mono- and/or di-unsaturated and behenic, m a molar ratio of unsaturates behenic of 1 7 to 3 5 A particularly prefened solid sugar polyester is the octaester of sucrose m which there are about 7 behenic fatty acid moieties and about 1 oleic acid moiety m the molecule The ester materials are further described m, U S Patent No 2,831,854, U S Patent No 4,005,196, to Jandacek, issued January 25, 1977, U S Patent No 4,005,195, to Jandacek, issued January 25, 1977, U S Patent No 5,306,516, to Letton et al , issued April 26, 1994, U S Patent No 5,306,515, to Letton et al , issued April 26, 1994, U S Patent No 5,305,514, to Letton et al , issued April 26, 1994, U S Patent No 4,797,300, to Jandacek et al , issued January 10, 1989, U S Patent No 3,963,699, to Rizzi et al, issued June 15, 1976, U S Patent No 4,518,772, to Volpenhein, issued May 21, 1985, and U S Patent No 4,517,360, to Volpenhem, issued May 21, 1985, all of which are incorporated by reference herein in their entirety J. Other Optional Components The compositions of the present invention may also include an extract obtained by suitable physical and/or chemical isolation from natural sources (e g , plants, fungi, by-products of microorganisms), including those known m the topical personal care art Preferred extracts are those which enhance the skin appearance benefits of the present invention, and which are preferably used in a safe and effective amount, more preferably an amount of from 0 1% to about 20%, even more preferably 0 5% to about 10%, also from 1% to about 5% Such extracts mclude plant and fungal extracts such as extracts of yeast, rice bran, and of the plant Centella Asiatica Natural extracts of Centella Asiatica are prefened and are commercially available from MMP, Inc of Plamfield, New Jersey under the trade name(s) Centella Asiatica E P C A ("Extract Punfied of Centella asiatica") and Genines amel Genmes amel is the purer form of the extract Compounds which are known to stimulate the production of collagen can also be used m the present invention Such compounds mclude Factor X (kmetin), Factor Z (zeatin), n-methyl taunne, dipalmitoyl hydroxyprolrne, palmitoyl hydroxy wheat protein, biopeptide CL (palmitoyl glycyl- histidyl-lysine), ASC III (Amplifier of Synthesis of Collagen III, E Merck, Germany), and beta glucan The compositions hereof can also include natural cerarmdes or the like, for example, ceramide 1 - 6 Other examples of additional components useful herem mclude the following water-soluble vitamms and derivatives thereof [e g , vitamin C], polyethyleneglycols and polypropyleneglycols, polymers for aiding the film-forming properties and substantivity of the composition (such as a copolymer of eicosene and vmyl pynohdone, an example of which is available from GAF Chemical Corporation as Ganex® V-220) Also useful are crosslinked and noncrosshnked nonionic and cationic polyacrylamides [e g , Salcare SC92 which has the CTFA designation polyquatermum 32 (and) mmeral oil, and Salcare SC 95 which has the CTFA designation polyquatermum 37 (and) mineral oil (and) PPG-1 tndeceth-6, and the nonionic Seppi-Gel polyacrylamides available from Seppic Corp ] Also useful are crosslinked and uncrosshnked carboxyhc acid polymers and copolymers such as those contaming one or more monomers denved from acrylic acid, substituted acrylic acids, and salts and esters of these acrylic acids and the substituted acrylic acids, wherem the crosslmkmg agent contams two or more carbon-carbon double bonds and is denved from a polyhydric alcohol (examples useful herein mclude the carbomers, which are homopolymers of acrylic acid crosslinked with allyl ethers of sucrose or pentaerytntol and which are available as the Carbopol® 900 series from B F Goodrich, and copolymers of C j o-30 alkyl acrylates with one or more monomers of acrylic acid, methacrylic acid, or one of their short chain (ι e ,C j _4 alcohol) esters, wherein the crosslmkmg agent is an allyl ether of sucrose or pentaerytntol, these copolymers bemg known as acrylates/C 10-30 alkyl acrylate crosspolymers and are commercially available as Carbopol® 1342, Pemulen TR-1, and Pemulen TR-2, from B F Goodrich) These carboxyhc acid polymers and copolymers are more fully described in U S Patent No 5,087,445, to Haffey et al , issued February 11, 1992, U S Patent No 4,509,949, to Huang et al , issued April 5, 1985, U S Patent No 2,798,053, to Brown, issued July 2, 1957, which are incorporated by reference herem See also, CTFA International Cosmetic Ingredient Dictionary, fourth edition, 1991, pp 12 and 80, which is also incorporated herem by reference Also useful herein are aesthetic components such as fragrances, pigments, colorings, essential oils, skin sensates, astringents, skm soothmg agents, skm healmg agents and the like, nonlimiting examples of these aesthetic components mclude clove oil, menthol, camphor, eucalyptus oil, eugenol, menthyl lactate, witch hazel distillate, bisabolol, dipotassmm glycyπhizinate and the Preparation of Compositions The compositions of the present mvention are generally prepared by conventional methods such as are known in the art of making topical compositions Such methods typically mvolve mixmg of the ingredients m one or more steps to a relatively uniform state, with or without heating, coolmg, application of vacuum, and the like Methods For Reducing Sebum Synthesis and Regulating the Oily/Shiny Appearance of Skin The subject mvention relates to methods of reducing sebum synthesis and regulatmg the oily and/or shmy appearance of skm Such methods comprise topically applymg to the skm to be treated an effective amount of the compositions of the subject mvention so as to deposit an effective amount of primary active on the skin The term "effective amount", as used herem, means an amount sufficient to reduce sebum synthesis and regulate oily and/or shmy appearance of skm as defined herem In general, a safe and effective amount of the primary actives are left m contact with the skm for a period sufficient to provide noticeable effects, generally after chronic application such as described herem The composition can be applied for several days, weeks, months or years at appropnate intervals The compositions are preferably applied from about four times a day to about once every three days, more preferably from about twice a day to once every other day, also about once a day, until a satisfactory reduction m sebum synthesis or oily and/or shmy skm appearance improvement has been achieved The reduction in sebum synthesis and the regulation of the appearance of oily and/or shmy skm can be observed visually without magnification Methods of quantifymg reduction m sebum synthesis and the regulation of the appearance of oily and/or shiny skm such as are known in the art can also be employed, e g , sebutape analysis such as known m the art Typically, m each application, an effective coatmg of the skin with primary active is achieved by topically applying (m terms of mg skin) from about 0 0002 mg/ cm 2 to about 0 5 mg/cm^ of primary active to the skm to be treated More preferably, from about 0 002 mg/cm^ to about 0 2 mg/cm^ of primary active is applied Most preferably, from about 0 02 mg/cm^ to about 0 1 mg/cm 2 of primary active is applied The amount of composition that is applied may be, for example, from about 0 01 mg to about 5 mg skm, preferably about 1 to about 2 mg composition/cnr skm The compositions are generally applied by lightly massaging the composition mto the skm, typically in the amounts described above The compositions of the invention can also be used for reducing sebum synthesis and regulatmg oihness of the scalp and for controlling dandruff Methods of regulating scalp oihness and for controlling dandruff are as described above, wherem the composition is applied to the scalp Examples The following examples further describe and demonstrate embodiments within the scope of the subject invention The examples are given solely for the purpose of illustration and are not to be construed as limitations of the subject mvention, as many vanations thereof are possible without departing from the spirit and scope of the mvention Example 1 A skin gel is prepared by conventional methods from the following components Blend the Phase A components with a suitable mixer until dissolved Separately, blend the Phase B components with a suitable mixer and heat to 70°C with mixing to melt the components Add the Phase C components to Phase B and mix until dispersed Begm to cool the batch, then add the D Phase Once Phase D is dispersed, add Phase A to the batch and continue coolmg and mixing When the batch reaches 40°C add the Phase E component and stir until completely dispersed Apply the composition to a subject's facial acne or oily/shiny skm at 2 mg composition/cm 2 skm once or twice daily for a period of from 2 weeks to 6 months to reduce facial oilmess and acne Example 2 The following lotions are prepared by mixing the ingredients in each composition accordmg to conventional mixmg techniques well known to those skilled m the art of formulating skm care compositions Any of the above compositions is applied to the face at a dose of 0 2 ml, up to four times a day to treat oily/shiny skm or existmg acne. Example 3- A skm cream is prepared by conventional methods from the following components Blend the A phase components with a suitable mixer (e g , Tek ar model RW20DZM), heatmg while stinmg to a temperature of 70-80°C Separately, blend the B phase components with a suitable mixer and heat with mixmg to melt the components Separately, blend the C phase components and mill to obtain an acceptably smooth mixture (e g , usmg a Tekmar T50 Mill) Add the C phase mixture to the B phase mixture and mix Then add the resultmg mix to the A phase mixture with mixing, cool with a cold water bath and mill, then continue stirring. Remove the combination from the bath, with contmued stirring, once the temperature reaches 40°C. Separately, blend the D phase components by stirring until dissolved, then add this to the combination of A-C materials Separately, blend the E phase components by mixmg until smooth and contmuous, then add this to the combmation of the A-D materials Add and mix the fragrance, then the NaOH. Adjust the pH as necessary to 5.5 Apply the composition to a subject's facial acne or oily/shmy skm at 2 mg composition/cm 2 skin once or twice daily for a period of from 2 weeks to 6 months to reduce facial oilmess and acne Example 4 An emulsion is prepared by conventional methods from the following components Form the water phase in a suitable vessel charged with the water as follows: add the glycerin and then niacinamide to the water with stining. Add to this mixture with stining the methyl paraben dissolved in the benzyl alcohol. Add to this mixture with stining the EDTA. Form the silicone phase in a separate suitable vessel by adding and stirring together the silicone fluids. Add the water phase to the silicone phase slowly with stirring to form the emulsion. Apply the composition to a subject's facial acne or oily skin at 2 mg composition/cm 2 skin once or twice daily for a period of from 2 weeks to 6 months to reduce facial oiliness and acne. Example 5: A skin cream is prepared by conventional methods from the following components. * A C1-C30 monoester or polyester of sugars and one or more carboxyhc acid moieties as described herein, preferably a sucrose polyester m which the degree of esteπfication is 7-8, and in which the fatty acid moieties are C18 mono- and/or di-unsaturated and behenic, in a molar ratio of unsaturates behenic of 1 7 to 3 5, more preferably the octaester of sucrose in which there are about 7 behenic fatty acid moieties and about 1 oleic acid moiety in the molecule, e g , sucrose ester of cottonseed oil fatty acids Blend the A phase components with a suitable mixer (e g , Tekmar model RW20DZM), heatmg while stining to a temperature of about 70-80°C Add the cetyl hyroxy ethyl cellulose and methyl paraben with mixmg at about 70-80°C to melt the components Separately, blend the C phase components and mill to obtain an acceptably smooth mixture (e g , usmg a Tekmar T50 Mill) Add the C phase mixture to the above mixture and mix Remove the combmation from the bath, with contmued stirring, once the temperature reaches about 45°C Add the dimethicone and Separately, blend the E phase components by mixmg until smooth and contmuous, then add this to the above mixture Add and mix in the benzyl alcohol, then the NaOH Adjust the pH as necessary to 7 Apply the composition to a subject's facial acne or oily skm at 2 mg composition/cm 2 skin once or twice daily for a period of from 2 weeks to 6 months to reduce facial oilmess and acne Example 6 A skm cream is prepared by conventional methods from the following components * See Example 5 Blend the A phase components with a suitable mixer (e.g., Tekmar model RW20DZM). Blend the B phase components into the A phase with a suitable mixer. Separately, blend the C phase components until they are uniform. Add the C phase mixture to the A/B phase mixture, mix until uniform and emulsified, and then mill to obtain an acceptably smooth mixture (e.g., using a Tekmar T50 Mill). Apply the composition to a subject's facial acne or oily skin at 2 mg composition/cm 2 skin once or twice daily for a period of from 2 weeks to 6 months to reduce facial oiliness and acne. Example 7: A bath oil having the composition A, B or C is prepared by combining the following components using conventional mixing and formulating techniques well known to those skilled in the art of skin care formulations. Apply the bath oil to the skin either as prepared or in aqueous diluted form. Apply in a dose of from 1-2 mg oil /cm 2 skin for four weeks, to observe a decrease in skin oil and/or shine. Example 8: A hair conditioner is prepared by combmmg the following components usmg conventional mixing and formulatmg techniques well known to those skilled in the art of skm care formulations Apply the conditioner to the scalp, preferably to clean hair, every other day to once a day to reduce the appearance of oily hair and the occunence of dandruff Apply a dose of about 0.5 ml and wash off. Example 9: A liquid shampoo havmg the composition A, B or C is prepared by combmmg the following components usmg conventional mixing and formulatmg techniques well known to those skilled in the art of skm care formulations Apply the shampoo to the scalp every other day to once a day to reduce the appearance of oily hair and the occunence of dandruff. A dose of about 0.5 ml is applied and washed off. Example 10: A topical composition suitable for use as a liquid make-up foundation is prepared from the following ingredients using conventional mixing and formulating techniques well known to those skilled in the art of skin care formulations. Apply the composition to a person's face once per day in an amount of 1-2 mg composition/cm 2 skin for four weeks, to observe a decrease in facial oil and/or shine, a reduction in oily breakthrough, longer wear of the composition, and more even coverage as time passes. Example 11 : A water-in-oil topical composition suitable for use as a liquid make-up foundation is prepared from the following ingredients using conventional mixing and formulating techniques such as described below. Combine the ingredients A and B in a suitable container. Mix the ingredients using a Silverson L4RT mixer equipped w/ a l" tubular assembly and a square hole screen for 30 minutes at 9000 rpm (the container can be covered to avoid loss of any volatile or other materials). Heat the resultant mixture to 85-90°C. Add ingredients C, mix for 5 minutes at 2100 rpm using a Silverson L4RT mixer equipped w/ a 2" head and a disintegrating screen. The container should be covered to minimize evaporation of cyclomethicone and other volatile or nonvolatile materials. Cool the resultant mixture to 45-55°C. Combine the ingredients D components and mix until a uniform slurry is formed. Separately, combine the ingredients E and mix until a uniform slurry is formed. Add the resultant slurries to the mixture of A, B and C (which is at 45-55°C), mix for 5 minutes at 2100 rpm using a Silverson L4RT equipped w/ a 2" head and a disintegrating screen. Cool the resultant mixture to 30° C, then add ingredient F Mix 5 minutes at 2100 rpm usmg a Silverson L4RT equipped w/ a 2" head and a disintegrating screen Combine the mgredients G m a suitable container and mix until all components are dissolved Slowly add the resultant solution to the mixture of A-F Emulsify this combmation using a Silverson L4RT mixer equipped w/ a 2" head and a dismtegratmg screen at 2100-5100rpm (rpms will increase as the mixture thickens), continue mixing for 5 minutes after all of the G mixture is added Apply the composition to a person's face once per day m an amount of 1-2 mg composition/cm 2 skin for four weeks, to observe a decrease m facial oil, a reduction m oily breakthrough, longer wear of the foundation, and more even coverage as the time penod passes While particular embodiments of the subject invention have been described, it will be obvious to those skilled in the art that various changes and modifications to the subject mvention can be made without departing from the spirit and scope of the mvention It is intended to cover, m the appended claims, all such modifications that are withm the scope of the subject mvention

Claims: WHAT IS CLAIMED IS: 1. A method of inhibiting sebaceous gland activity in mammalian skin and scalp characterized in that it comprises the step of administering to the skin or scalp of a mammal susceptible to having excessive sebaceous gland activity a topical composition comprising: (a) a safe and effective amount of dehydroacetic acid or pharmaceutically- acceptable salts thereof, and (b) a dermatologically-acceptable carrier. 2. A method of regulating oily and/or shiny skin appearance characterized in that it comprises the step of administering to the skin or scalp of a mammal susceptible to oily and/or shiny skin a topical composition comprising: (a) a safe and effective amount of dehydroacetic acid or pharmaceutically- acceptable salts thereof, and (b) a dermatologically-acceptable carrier. 3. The method according to Claim 1 or 2 wherein said topical composition further comprises material selected from a sebum spreading material, a sebum absorbing material, and mixtures thereof. 4. A topical composition for inhibiting excessive sebaceous gland activity and/or for regulating oily and/or shiny skin appearance in mammals characterized in that it comprises: (a) a safe and effective amount of dehydroacetic acid or pharmaceutically- acceptable salts thereof, (b) a sebum absorbing material, and (c) a dermatologically-acceptable carrier. 5. A topical composition according to Claim 4 further comprising a sebum spreading reduction material wherein said sebum spreading reduction material is selected from the group consisting of coamidoprpyl hydroxysultaine, quaternary halide of N,N,N-trialkylaminoalkylene gluconamide, ammonium lauryl sulfate, triethanolamine lauryl sulfate, a straight chain dimethyl silicone polymer having the formula: (CH 3 ) 3 Si - OSi(CH 3 ) 2 ^ CH 3 wherein n is a positive integer sufficient to provide a silicone polymer having a molecular weight of about 50,000 or more and a viscosity of about 10,000 centistokes or more, and mixtures thereof. 6. A method of regulating oily and/or shiny skin appearance in mammals characterized in that it comprises the step of administering to the skin of a mammal susceptible to oily and/or shiny skin a topical composition comprising: (a) a safe and effective amount of dehydroacetic acid or pharmaceutically- acceptable salts thereof, (b) an ancillary sebosupressive active, and (c) a dermatologically-acceptable carrier. 7. A topical composition for regulating oily and/or shiny skin appearance in mammals characterized in that it comprises: (a) a safe and effective amount of dehydroacetic acid or a pharmaceutically-acceptable salts thereof, (b) an ancillary sebosupressive active, and (c) a dermatologically-acceptable carrier. 8. A composition according to Claim 7 wherein said ancillary sebosupressive active is selected from the group consisting of a vitamin B3 compound, tocopherol nicotinate, pyridoxine, panthenol, pantothenic acid, tioxolone, hesperetin, and mixtures thereof. 9. A composition according to Claim 7 or 8 wherein said ancillary sebosuppressive active is niacinamide. 10. A method of treating acne in mammalian skin characterized in that it comprises the step of administering to a mammal susceptible to or having acne a topical composition comprising: (a) a safe and effective amount of dehydroacetic acid or pharmaceutically- acceptable salts thereof, and (b) a dermatologically-acceptable carrier. 11. A topical composition for treating acne in mammalian skin or scalp characterized in that it comprises: (a) a safe and effective amount of dehydroacetic acid or pharmaceutically- acceptable salts thereof, (b) an ancillary anti-acne active, and (b) a dermatologically-acceptable carrier. 12. A method of regulating skin condition in mammalian skin characterized in that it comprises the step of administering to a mammal having skin wrinkles, fine lines, or large pores, a topical composition comprising: (a) a safe and effective amount of dehydroacetic acid or pharmaceutically- acceptable salts thereof, (b) a compound selected from the group consisting of organic acids, keto acids, retinoids, and mixtures thereof, and (c) a dermatologically-acceptable carrier.

Inventors: BIEDERMANN KIMBERLY ANNE, PARRAN JOHN JOSEPH, SCHUBERT HARRY L, BIEDERMANN, KIMBERLY, ANNE, PARRAN, JOHN, JOSEPH, SCHUBERT, HARRY, L.
Applicants: PROCTER & GAMBLE, THE PROCTER & GAMBLE COMPANY
Application year: 1998
Main classification: A61K7
IPC codes: A61K8, A61K31, A61P17, A61Q1, A61Q5, A61Q19